

=> d his

(FILE 'HOME' ENTERED AT 12:09:39 ON 10 FEB 2005)

FILE 'REGISTRY' ENTERED AT 12:09:47 ON 10 FEB 2005

L1 STRUCTURE UPLOADED

L2 9 S L1


L3 127 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:10:35 ON 10 FEB 2005

L4 40 S L3

=> d que 14 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 127 SEA FILE=REGISTRY SSS FUL L1

L4 40 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d 1-40 bib abs hitstr

L4 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM

AN 2004:927028 CAPLUS

DN 141:395548

TI Preparation of (-)-1-(4-sulfamylphenyl)-3-substituted-5-heteroaryl-2-pyrazolines as inhibitors of cyclooxygenase-2 (COX-2)

IN Reddy, Premkumar E.; Reddy, Ramana M. V.; Bell, Stanley C.

PA Temple University of the Commonwealth System of Higher Education, USA; Oncoviva Therapeutics, Inc.

SO PCT Int. Appl., 46 pp.



CODEX: P1XX02

DT Patent

LA English


FAM. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO	2004/093829	A2	2004/1104
	WO	2004/US8358		2004/0319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: BW, GH, GM, KE, LS, MK, MZ, SD, SL, SZ, TZ, UG, ZM, ZH, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US	2003-459415P	P	20030331
OS	MARPAT	141:395548		
GI				



AB The (-)-enantiomers the title 2-pyrazolines, such as I (R = NH₂, acylamino, etc.; R₃ = haloalkyl; R₅ = heteroaryl), were prepared for use in pharmaceutical compns. as COX-2 inhibitors. These pyrazolines are claimed for use in treating cyclooxygenase-mediated disorders, such as inflammation, neoplastic disorders and angiogenesis-mediated disorders.


L4 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)



RN 787623-47-6 CAPLUS

CN Benzenesulfonamide, 4-[5-(7-chloro-1H-indol-3-yl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 787623-50-1 CAPLUS

CN Benzenesulfonamide, 4-[5-(5-chloro-1H-indol-3-yl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



L4 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)

Further, these pyrazolines are claimed for use in treating, inhibiting or delaying the onset of Alzheimer's disease, presenile dementia, schizophrenia, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, cerebral ischemia or stroke. Thus, (-)-1-(4-sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline (II) was prep'd. via resolin. of the corresponding racemate using an HPLC system with a ChiralPak AD column. The prep'd. pyrazolines were assayed for inhibition of COX-2 activity.

II 787623-45-4P, (-)-1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline 787623-46-5P, (+)-1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline 787623-47-6P, (-)-1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(7-chloroindol-3-yl)-2-pyrazoline 787623-50-1P, (+)-1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(7-chloroindol-3-yl)-2-pyrazoline


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (-)-1-(4-sulfamylphenyl)-3-substituted-5-heteroaryl-2-pyrazolines as inhibitors of cyclooxygenase-2)

RN 787623-45-4 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-5-(1H-indol-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 787623-46-5 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-5-(1H-indol-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)


IT 313236-73-6P, 1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (-)-1-(4-sulfamylphenyl)-3-substituted-5-heteroaryl-2-pyrazolines as inhibitors of cyclooxygenase-2)

RN 313236-73-6 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-5-(1H-indol-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




IT 787623-48-7, 1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(7-chloroindol-3-yl)-2-pyrazoline

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of (-)-1-(4-sulfamylphenyl)-3-substituted-5-heteroaryl-2-pyrazolines as inhibitors of cyclooxygenase-2)

RN 787623-48-7 CAPLUS

CN Benzenesulfonamide, 4-[5-(7-chloro-1H-indol-3-yl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:365658 CAPLUS
 DN 140:365445
 TI Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application
 AU Salgado, Leonardo; Encina, Gregorio; Farran, Ramon; Puig, Santiago; Martinez, Luis
 CS Laboratorios Dr. Esteve, Pharmacokinetics and Drug Metabolism Department, Barcelona, Spain
 SO Chirality (2004), 16(5), 302-308
 CODEN: CHIRLEP; ISSN: 0899-0042
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 AB E-6087 is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2. Because E-6087 has a chiral center, this compound is a racemic mixture of two stereoisomers, (+)-(R)-E-6087 (E-6231) and (-)-(S)-E-6087 (E-6232). A normal-phase liquid-chromatog. method for the enantioselective determination of E-6087 in human plasma was developed and validated. The samples were extracted using solid-phase extraction cartridges containing C18 sorbent, and the exts. were redissolved in absolute ethanol and injected into the chromatog. system. The enantiomeric separation was achieved on a chiral stationary-phase column of derivatized amylose, and the enantiomers were quantified by fluorescence detection. The method was validated for drug concns. ranging from 5 to 400 ng/mL for both enantiomers. No peaks interfering with the quantification of enantiomers were observed. The limit of quantification was 5 ng/mL, with precision expressed as a coefficient of variation lower than 10.6% and accuracy expressed as relative error lower than 12.2%. The utility of this method was demonstrated by anal. of plasma samples from healthy volunteers given an oral dose of rac-E-6087. Peak plasma levels of E-6231 were higher than levels obtained for E-6232. Results were consistent with those obtained with a conventional reversed-phase method used for determination of the racemic compound
 IT 251442-94-1, E-6087 251443-65-9, E-6231
 251443-66-0, E-6232
 RL: ANT (Analyte); PKT (Pharmacokinetics); ANST (Analytical study); BIOL (Biological study)
 (enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: validation and pharmacokinetic application)
 RN 251442-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RE, CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-65-9 CAPLUS
 CN Benzenesulfonamide, 4-[(5R)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS
 CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:182691 CAPLUS
 DN 140:210765
 TI Method using dialkyl ethers and other compounds for treating arthritis, cartilage damage, and other interleukin 6-mediated conditions
 IN Cornicelli, Joseph Anthony; Kilgore, Kenneth Stanley; Siskovic, Drago Robert; Bove, Susan Elizabeth; Neldeffer, David Herbert; Kowala, Mark Charles
 PA Warner-Lambert Company LLC, USA
 SO PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN, CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004017952	A1	20040304	WO 2003-183664	20030813
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004048910	A1	20040311	US 2003-639719	20030812
PRAL US 2002-405250P	P	20020622		
US 2003-475433P	P	20030603		
US 2003-477092P	P	20030609		
US 2003-484808P	P	20030703		
OS MARPAT 140:210765				
AB The invention discloses combinations, compns., and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, including joint pain, and the like in a patient in need thereof. Comps. of the invention include e.g. 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid calcium salt (CI-1027). IT 251442-94-1 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (dialkyl ethers and other compds. for treating arthritis, cartilage damage, and other interleukin 6-mediated conditions) RN 251442-94-1 CAPLUS CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)				

L4 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RE.ONT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STN

AN 2003:405103 CAPLUS

DN 140:117541

TI Determination of enantiomeric purity of a novel COX-2 anti-inflammatory drug by capillary electrophoresis using single and dual cyclodextrin systems

AU Perez-Maseda, Carlos; Calvet, Carme; Cuberes, Rosa; Frigola, Jordi
CS Medicinal Chemistry Department, Laboratorios Dr. Esteve S.A., Barcelona, E-08041, Spain

SO Electrophoresis (2003), 24(9), 1416-1421

COGEN: ELCTDN; ISSN: 0173-0835

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

AB E-6087 is the most advanced compound among the cyclooxygenase-2 (COX-2) inhibitor drugs developed in the authors' company. Its activity is mainly associated with the S(-)-enantiomer (E-6232), whereas the R(+)-enantiomer (E-6231) becomes an impurity whose content should be determined. Five main impurities and degradation products of E-6232 were found (E-6144, E-6024, E-6072, E-6397 and E-6132), and some of them co-elute with the dimer when using a chiral high-performance liquid chromatog. (HPLC) method. Consequently, the authors have optimized the separation of all the impurities from the 2 enantiomers of E-6087 by capillary electrophoresis (CE), to use the method for the enantiomeric purity determination of E-6232. The effect of the MeOH content in the background electrolyte (BGE), the sulfolbutyl ether- β -cyclodextrin (SBE- β -CD) and heptakis-(2,6-di-O-methyl)- β -cyclodextrin (DM- β -CD) concentration, and the capillary temperature were studied. Separation of all compds. could be achieved in different systems, either in a single CD-system (with SBE- β -CD) or in a dual CD-system (with DM- β -CD as a neutral CD). By using the dual CD system a limit of detection (LOD) and a limit of quantitation (LOQ) of 0.03% and 0.1% of dimer, resp., were achieved.

IT 251442-94-1, (z)-E 6087 251442-99-6, (z)-E 6024

251443-07-9, (z)-E 6072 251443-41-1, (z)-E 6144

251443-65-9, (R)-E 6231 251443-66-0, (S)-E 6232


RL: ANT (Analyte); ANST (Analytical study)

(determination of enantiomeric purity of a novel COX-2 anti-inflammatory drug by capillary electrophoresis using single and dual cyclodextrin systems)

RN 251442-94-1 CAPLUS


ON Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 251442-99-6 CAPLUS

ON Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 251443-07-9 CAPLUS


ON Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 251443-41-1 CAPLUS

ON Benzenesulfonamide, 4-[(4,5-dihydro-3-(trifluoromethyl)-5-(2,3,4-trifluorophenyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 251443-65-9 CAPLUS

ON Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS

ON Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.ONT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:977795 CAPLUS

DW 138:55962

TI Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-4,5-pyrazolines that are racemic and enantiomerically pure via resolution with ephedrine.

IN Alcon-Marrugat, Montserrat; Pericas-Brondo, Miguel Angel; Cuberes-Altisen, Maria Rosa; Frigola-Constansa, Jordi

PA Laboratorios Del Esteve, S.A., Spain

SD PCT Int. Appl. 30 pp.

COVEN: PXXX02


DT Patent

LA Spanish

FAN.CH1 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE	
PI	MO	2002102701	A1	20021227	MO 2002-ES274	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PA, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
ES	2183720	A1	20030316	ES	2001-1412	20010618
ES	2183720	B1	20040116			
EP	1408035	A1	20040414	EP	2002-735442	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
EE	200400016	A	20040415	EE	2004-16	20020606
BR	2002011009	A	20041103	BR	2002-11009	20020606
JP	200502604	T2	20050127	JP	2003-505323	20020606
US	2004019222	A1	20040129	US	2002-312194	20021217
US	6946935	B2	20050125			
BG	108524	A	20040831	BG	2004-108524	20040113
PRAT	ES	2001-1412	A	20010618		
	MO	2002-ES274	W	20020606		
OS	CASREACT	138:55962	MARPAT	138:55962		
GI						

L4 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The invention relates to a method of obtaining pyrazole derivs. I, which includes racemic mixts. (±)-I and the enantiomerically pure compds. (-)-I and (+)-I (wherein: R1, R3 = H, Cl, F, Me, CF3, or OMe; R2 = H, Cl, F, Me, CF3, OMe, OCF3, SO2Me, or SO2NH2; R4 = H, Cl, F, Me, CF3, OMe, OCF3, SO2Me, or SO2NH2; provided that one of R2 or R4 = SO2Me or SO2NH2). I are cyclooxygenase-2 inhibitors, useful as antiinflammatories, which are known from WO 99/62884. The method allows use of economical (un)substituted benzaldehydes and phenylhydrazines, instead of more expensive 4-methylsulfonyl- and 4-aminosulfonyl-substituted compds. The method involves production of racemic (±)-I by reaction of an (E)-1,1,1-trifluoro-4-aryl-3-buten-2-one with a phenylhydrazine, followed by treatment with chlorosulfonic acid, or by reaction with chlorosulfonic acid followed by reaction with sodium hydroxide and, finally, with thionyl chloride. The product obtained by any of the aforementioned methods (i.e., the sulfonyl chloride) then reacts with ammonium carbonate or ammonia, or with sodium sulfite and then Me iodide or di-Me sulfate. To produce enantiomerically pure I via resolution of (±)-I, the resolution is carried out with optically active ephedrine, followed by formation of the sodium salt of each of the enantiomers, reaction of these with (a) thionyl chloride and then ammonia or ammonium carbonate, or (b) with thionyl chloride followed by sodium sulfite and then Me iodide or di-Me sulfate, giving (+)- and (-)-I. For instance, (S)-(-)-II was prepared in 5 steps, by: (1) cyclocondensation of (E)-1,1,1-trifluoro-4-(2,4-difluorophenyl)-3-buten-2-one with PhNHNH2.HCl in the presence of p-MeC6H4SO3H.H2O to give (±)-1-phenyl-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole in 65% yield; (2) chlorosulfonation of the latter with ClSO3H and hydrolysis with NaOH to give (±)-Na 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonate [(±)-III.Na] in 75% yield; (3) resolution of the latter with (+)-ephedrine.HCl [(+)-IV.HCl] in CHCl3 to give (-)-III, (+)-IV salt with

L4 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


>98% enantiomeric excess (ee); (4) treatment of the salt with NaCl and NaOH in iso-PrOH to give (-)-III.Na; and (5) treatment of this with SOCl2, and then (NH4)2CO3, to give (S)-(-)-II in 84% yield and >99% ee after recrystn. The invention sulfone (R)-(-)-V was similarly prep., using the other method variant with Na2SO3 and MeI.

II 251443-66-OP, (S)-(-)-4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (target compound: improved, economical preparation of diaryl(trifluoromethyl)pyrazoline enantiomers from benzaldehydes and phenylhydrazines via ephedrine resolution)

RN 251443-66-0 CAPLUS


CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CH1 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:856309 CAPLUS
 DN 139:17018
 TI Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis
 AU Penas-Masada, C.; Calvet, C.; Cuberes, R.; Frigola, J.
 CS Medicinal Chemistry Department, Laboratorios Dr. Esteve S.A., Barcelona, E-08041, Spain
 SO Bioforum International (2002), 6(5), 275-277
 CODEN: BINTFO; ISSN: 1434-2693
 PB GIT Verlag GmbH & Co. KG
 DT Journal
 LA English
 AB A capillary electrophoresis (CE) method was developed for the enantioseparation of three novel COX-2 inhibitor drugs (E-6259, E-6036 and E-6087) with anti-inflammatory and analgesic activities using sulfolobus- β -cyclodextrin (SBE- β -CD) as a chiral selector. The use of 50 mM sodium tetraborate at pH 9.2, 7.1 mM SBE- β -CD and 30 % MeOH (volume/volume), as a background electrolyte (BGE), allowed the complete enantioseparation of the three neutral racemates and their corresponding metabolites in a single run. Migration times were shortened by adding 1.75 mM dimethyl- β -cyclodextrin (DM- β -CD) to the previous BGE (dual CD system). The reversal of the migration order of E-6259 enantiomers in the dual CD system was also studied.
 IT 251442-94-1P, (±)-E 6087 251443-65-9P, (R)-E 6232
 251443-66-0P, (S)-E 6232
 RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical study); PREP (Preparation)
 (enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis)
 RN 251442-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 251443-65-9 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:793411 CAPLUS
 DN 137:310911
 TI Utilization of pyrazoline derivatives, as inhibitors of the expression of the gene responsible for COX-2 synthesis, in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
 IN Cuberes-Altisent, Maria Rosa; Berrocal-Romero, Juana Maria; Contijoch-Llobet, Maria Montserrat; Frigola-Constans, Jordi
 PA Laboratorios del Esteve, S.A., Spain
 SO PCT Int. Appl., 54 pp.
 CODEN: PDIQD2
 DT Patent
 LA Spanish
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2002080909	A1	20021017	MO 2002-ES137	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2174757	A1	20021101	ES 2001-818	20010406
ES 2174757	B1	20031101		
EP 1384477	A1	20040128	EP 2002-714233	20020321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 200208805	A	20040713	BR 2002-8805	20020321
JP 2004525166	T2	20040819	JP 2002-578948	20020321
US 2004034082	A1	20040219	US 2002-312193	20021217
NO 2003004470	A	20031205	NO 2003-4470	20031006
PRAT ES 2001-818	A	20010406		
MO 2002-ES137	W	20020321		
OS HARPAT 137:310911				
GI				




L4 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


AB The invention relates to pyrazoline derivs. I [wherein R1 = H, Me, CH2F, CHF2, CF3, CO2H, C1-4 alkoxy, carbonyl, CONH2, or cyano; R2 = H or Me; R3, R4, R7, R8 = H, Cl, F, Me, CF3, or OMe; R5, R6 = H, Cl, F, Me, CF3, OMe, OCF3, SO2Me, SO2NH2, or SO2NHAc, provided that 1 of R5 or R6 = SO2Me, SO2NH2, or SO2NHAc, and provided that 1 of R1 = Me, then: R2 = H or Me; R3 and R8 = H, Cl, F, Me, or CF3; R4 = H, F, Me, CF3, or OMe; R5 = F, CF3, CF3O, SO2Me, SO2NH2, or SO2NHAc; R6 = H, Cl, F, Me, CF3, OMe, OCF3, SO2Me, SO2NH2, or SO2NHAc, provided that 1 of the substituents R5 or R6 = SO2Me, SO2NH2, or SO2NHAc; and R7 = H, Cl, F, Me, CF3, or OMe; including physiologically acceptable salts]. I are useful for the prevention or treatment of proliferative cell diseases. In particular, I are useful for treatment of pre-neoplastic or neoplastic processes, tumoral angiogenesis, cachexia, and processes related to tumor necrosis factor (TNF). Generally, I are useful for treating processes where there would be benefit by inhibiting the expression of the gene responsible for the synthesis of cyclooxygenase 2 (COX-2), notably in mammals, and particularly in humans. A list of 84 specific examples is provided, and a similar list of 84 compds. (1 difference) is claimed. Six examples of individual enantiomers are given, the remainder being racemic. For instance, condensation of 2,4-difluorobenzaldehyde with either CHOCOCF3 (688) or the reaction product of LiCH2PO3Et2 with PhN:C(Cl)CF3 (618) gave (E)-1,1,1-trifluoro-4-(2,4-difluorophenyl)-3-buten-2-one. Cyclocondensation of the latter enone with 4-(H2N)SO2C6H4NH2.HCl gave 618 invention compound (±)-II, which was resolved by chromatog. on CHIRALPAK AS to give (+)- and (-)-II with enantiomeric purities of 99.98 or greater. In tests against human colorectal cancer cell lines HCT59 and TD20, (±)-II had IC50 values of 29.87 and 33.87 μ M, resp. I also inhibited the induction of COX-2 in JURKAT cells, were active against breast cancer cells in culture (IC50 12-18 μ M), inhibited angiogenesis (as determined by induction of expression of VEGF and TF in cell culture), and inhibited production of TNF- α in the air-pouch model in mice.
 IT 251442-94-1P, 1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (drug candidate, resolution; preparation and use of pyrazoline derivs. as COX-2 gene expression inhibitors for prevention and/or treatment of proliferative cell diseases)
 RN 251442-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 251443-65-9P, (+)-1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-66-0P, (-)-1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate: preparation and use of pyrazoline derivs. as COX-2 gene expression inhibitors for prevention and/or treatment of proliferative cell diseases)
 RN 251443-65-9 CAPLUS
 CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS
 CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

5-phenyl-1H-pyrazole-3-carboxamide 251443-31-9P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-methylphenyl)-1H-pyrazole-3-carboxamide 251443-34-2P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(3,4-dimethylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-35-3P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(3-methyl-4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-36-4P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-37-5P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-fluoro-4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-38-6P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2,4-dimethoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-39-7P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-fluoro-2-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-40-0P, 1-(4-Aminosulfonylphenyl)-3-difluoromethyl-4,5-dihydro-5-(2,4-dimethylphenyl)-1H-pyrazole 251443-41-1P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2,3,4-trifluorophenyl)-3-trifluoromethyl-1H-pyrazole 251443-42-2P, 1-(4-Aminosulfonylphenyl)-5-(2-chloro-4-fluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-43-3P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-fluoro-4-trifluoromethylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-44-4P, 1-(4-Aminosulfonylphenyl)-5-[2,4-bis(trifluoromethyl)phenyl]-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-45-5P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-methyl-3-fluorophenyl)-3-trifluoromethyl-1H-pyrazole 251443-46-6P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-methyl-4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-47-7P, 1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-3-difluoromethyl-4,5-dihydro-1H-pyrazole 251443-48-0P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-fluoro-2-trifluoromethylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-50-2P, 1-(4-Aminosulfonylphenyl)-5-(2-chlorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-51-3P, 1-(4-Aminosulfonylphenyl)-5-(4-chloro-2-fluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-52-4P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-fluoro-2-methylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-53-5P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-fluoro-4-methylphenyl)-3-trifluoromethyl-1H-pyrazole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate: prep. and use of pyrazoline derivs. as COX-2 gene expression inhibitors for prevention and/or treatment of proliferative cell diseases)


RN 123909-93-3 CAPLUS
 CN Benzenesulfonamide, 4-[(4S)-4,5-dihydro-3-methyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 123909-93-3P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-3-methyl-5-(4-methylphenyl)-1H-pyrazole 251442-92-9P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazole 251442-95-3P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-phenyl-3-trifluoromethyl-1H-pyrazole 251442-99-6P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-fluorophenyl)-3-trifluoromethyl-1H-pyrazole 251443-02-4P, 1-(4-Aminosulfonylphenyl)-5-(3,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-04-6P, 1-(4-Aminosulfonylphenyl)-5-(2,4-dichlorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-05-7P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-methylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-06-0P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(3-methylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-07-9P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2-fluorophenyl)-3-trifluoromethyl-1H-pyrazole 251443-09-1P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(3-fluorophenyl)-3-trifluoromethyl-1H-pyrazole 251443-11-5P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 251443-12-6P, 1-(4-Aminosulfonylphenyl)-5-(3-chloro-4-fluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-13-7P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-3-trifluoromethyl-5-(4-trifluoromethoxyphenyl)-1H-pyrazole 251443-14-0P, 1-(4-Aminosulfonylphenyl)-5-(2,3-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole 251443-15-9P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(2,4-dimethylphenyl)-3-trifluoromethyl-1H-pyrazole 251443-17-1P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-fluorophenyl)-3-methyl-1H-pyrazole 251443-20-6P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-3-methyl-5-(4-trifluoromethylphenyl)-1H-pyrazole 251443-24-0P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-(4-methylphenyl)-1H-pyrazole-3-carboxylic acid 251443-25-1P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-5-phenyl-1H-pyrazole-3-carboxylic acid 251443-27-3P, Methyl 1-(4-aminosulfonylphenyl)-4,5-dihydro-5-(4-methylphenyl)-1H-pyrazole-3-carboxylate 251443-28-4P, Methyl 1-(4-aminosulfonylphenyl)-4,5-dihydro-5-phenyl-1H-pyrazole-3-carboxylate 251443-30-0P, 1-(4-Aminosulfonylphenyl)-4,5-dihydro-


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251442-92-9 CAPLUS
 CN Benzenesulfonamide, 4-[(4S)-4,5-dihydro-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251442-96-3 CAPLUS
 CN Benzenesulfonamide, 4-[(4S)-4,5-dihydro-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251442-99-6 CAPLUS
 CN Benzenesulfonamide, 4-[(5S)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)



RN 251443-02-4 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-04-6 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2,4-dichlorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-05-7 CAPLUS


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)



RN 251443-09-1 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-11-5 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(4-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-12-6 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3-chloro-4-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)

CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-06-8 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-07-9 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)



RN 251443-13-7 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-14-8 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2,3-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-15-9 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2,4-dimethylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-17-1 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-3-methyl-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-20-6 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-24-0 CAPLUS


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-30-8 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 251443-31-9 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 251443-34-2 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3,4-dimethylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 251443-25-1 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 251443-27-3 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 251443-28-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-35-3 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxy-3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-36-4 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-37-5 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2-fluoro-4-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-38-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-dimethoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-39-7 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluoro-2-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-40-0 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(2,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251443-43-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-[2-fluoro-4-(trifluoromethyl)phenyl]-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-44-4 CAPLUS
 CN Benzenesulfonamide, 4-[5-[2,4-bis(trifluoromethyl)phenyl]-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-45-5 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3-fluoro-2-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-41-1 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(trifluoromethyl)-5-(2,3,4-trifluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-42-2 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-chloro-4-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251443-46-6 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxy-2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 251443-47-7 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(2,4-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-48-8 CAPLUS
 CN Benzenesulfonamide, 4-[5-[4-fluoro-2-(trifluoromethyl)phenyl]-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-50-2 CAPLUS

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-[5-(2-chlorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-51-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chloro-2-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-52-4 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluoro-2-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:623722 CAPLUS
 DN 138:73198
 TI Synthesis of novel cyclic benzenesulfonylurea and thiourea derivatives
 AU Faidallah, Hassan M.; Albar, Hassan A.; Makki, Mohamed S. I.; Sharshira, E. M.
 CS Chemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt
 SO Phosphorus, Sulfur and Silicon and the Related Elements (2002), 177(3), 685-693
 CODEN: PSSLEC; ISSN: 1042-6507
 PB Taylor & Francis Ltd.
 DT Journal
 LA English
 OS CASREACT 138:73198
 AB Treatment of the pyrazoline derivs. with isocyanates or isothiocyanates afforded ureas and thioureas in a good yield. Subsequent treatment of the benzenesulfonylthioureas with α - and β -halogenocarbonyl compds. gave the corresponding thiazolidines and 1,3-thiazolidones resp. When urea derivs. were reacted with di-Me malonate in sodium ethoxide, they gave the corresponding pyrazolebarbiturate derivs. The structure of the isolated product were determined by the spectral methods.
 IT 100714-94-1 403479-69-6 403479-70-9 403479-71-0 403479-72-1 403479-73-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation cyclic benzenesulfonylurea and thiourea derivs.)
 RN 100714-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-69-6 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(2-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251443-53-5 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-fluoro-4-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RE CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 403479-70-9 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-71-0 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-phenyl-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-72-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-bromophenyl)-4,5-dihydro-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 403479-73-2 CAPLUS
CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methylphenyl)-5-(3-thienyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 251443-65-9 CAPLUS
CN Benzenesulfonamide, 4-[(5R)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS
CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:505977 CAPLUS

DN 137:375361

TI Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems

AU Calvet, Carmen; Cuberes, Rosa; Perez-Masada, Carlos; Frigola, Jordi
CS Medicinal Chemistry Department, Laboratorios Dr. Esteve S. A., Barcelona, E-08041, Spain

SO Electrophoresis (2002), 23(11), 1702-1708

CODEN: ELCTDN; ISSN: 0173-0835

PB Wiley-VCH Verlag GmbH

DT Journal

LA English


AB A capillary electrophoresis method was developed for the enantioseparation of three novel cyclooxygenase-2 (COX-2) inhibitor drugs (E-6259, E-6036 and E-6087) with anti-inflammatory and analgesic activities using sulfolobyl ether- β -cyclodextrin (SBE- β -CD) as a chiral selector. The use of 50 mM sodium tetraborate at pH 9.2 with 30% volume/volume methanol, containing 7.1 mM SBE- β -CD, as a background electrolyte (BGE) allowed the complete enantioseparation of the three neutral racemic mixtures (resolution = 2.4, 3.0 and 8.7, resp.) and their corresponding metabolites (oxidation products) in a single run. Migration times were shortened with some loss of enantioselectivity by adding 1.75 mM dimethyl- β -cyclodextrin (DM- β -CD) to the previous BGE (dual CD system). The reversal of the migration order of E-6259 enantiomers in the dual CD system was also studied. Furthermore, the addition of DM- β -CD to the BGE introduced a new chemoselectivity in the system that allowed E-6259 to be separated from the structurally similar compound E-6036.

IT 251442-94-1 251443-65-9 251443-66-0

RL: ANT (Analyte); ANST (Analytical study)
(enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems)

RN 251442-94-1 CAPLUS

CN Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:78060 CAPLUS

DN 136:318794

TI Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs

AU Reinoso, Raquel F.; Farran, Ramon; Moragon, Trinidad; Garcia-Soret, Antonio; Martinez, Lluís

CS Department of Pharmacokinetics and Drug Metabolism, Laboratorios Dr. Esteve S.A., Barcelona, 08041, Spain

SO Biopharmaceutics & Drug Disposition (2001), 22(6), 231-242

CODEN: BDDID8; ISSN: 0142-2782

PB John Wiley & Sons Ltd.

DT Journal

LA English


AB The pharmacokinetics of E-6087, a newly developed cyclooxygenase-2 inhibitor, was studied in rats and dogs after single oral and i.v. doses. In both animal species, E-6087 was characterized by a long elimination half-life (20-35 h), a low plasma clearance (0.10-0.22 l h⁻¹ kg⁻¹) and a relatively large volume of distribution (2-6 l kg⁻¹). Oral bioavailability was lower in dogs than in rats whereas a faster elimination was found in rats. Multiple peaks were present regardless of administration route and animal species, suggesting the existence of enterohepatic circulation. Gender effect on the pharmacokinetics of E-6087 was only found in rats, with greater exposure and longer elimination in females than in males. Food intake reduced the bioavailability (22%) with no apparent changes in the absorption rate. After oral dosing of 1, 5 and 25 mg kg⁻¹ to rats, linearity was lost at the highest dose due to the low aqueous solubility of E-6087. Drug absorption was improved by micronization. E-6087 and E-6132, (a pharmacol. active metabolite), showed different pharmacokinetics. The higher percentage of E-6087 at early times suggests that E-6087 is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times.

IT 251442-94-1, E 6087

RL: PKT (Pharmacokinetics); THU (Therapeutic use); B10L (Biological study); USES (Uses)
(pharmacokinetics of E-6087 in rats and dogs)


RN 251442-94-1 CAPLUS

CN Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:808786 CAPLUS
 DN 136:232229
 TI Synthesis of new pyrazoles from chalcones
 AU Faldallah, H. M.; Makki, Mohamad S. I.; Albar, H. A.; Sharshira, E. M.
 CS Chemistry Department, Alexandria University, Alexandria, Egypt
 SO Indian Journal of Heterocyclic Chemistry (2001), 11(1), 21-26
 CODEN: IJCHEI; ISSN: 0971-1627
 PB Prof. R. S. Varma
 DT Journal
 LA English
 OS CASREACT 136:232229
 AB Condensation of chalcones with p-sulfamylphenylhydrazine hydrochloride in presence of sodium acetate afforded the corresponding hydrazones. Subsequent boiling of the hydrazones in ethanol containing few drops of hydrochloric acid gave the corresponding pyrazolines. Oxidation of the pyrazolines with aqueous bromine furnished 3,5-disubstituted pyrazoles. When pyrazolines were treated with bromine in chloroform, they underwent oxidative bromination giving the dibromopyrazoles.
 IT 100714-94-1P 403479-69-6P 403479-70-9P
 403479-71-0P 403479-72-1P 403479-73-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazoles from chalcones)
 RN 100714-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-furanyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-69-6 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(2-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 403479-70-9 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-71-0 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-phenyl-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 403479-72-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-bromophenyl)-4,5-dihydro-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 403479-73-2 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(4-methylphenyl)-5-(3-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:182563 CAPLUS
 DN 135:70541
 TI Development and validation of two chromatographic methods for the quantification of E-6087 and one of its metabolites, E-6132, in rat plasma
 AU Reinos, R. F.; Farnen, R.; Moragon, I.; Garcia-Soret, A.; Martinez, L.
 CS Department of Pharmacokinetics and Drug Metabolism, Laboratorios Dr Esteve, Barcelona, S.A., 08041, Spain
 SO Journal of Pharmaceutical and Biomedical Analysis (2001), 24(5-6), 897-911
 CODEN: JPBADE; ISSN: 0731-7085
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB E-6087 is a nonsteroidal anti-inflammatory compound under development that selectively inhibits cyclooxygenase-2. In vitro studies have shown that one of its metabolites, E-6132, also inhibits this enzyme. Due to chromatographic reasons, two reverse phase HPLC methods were developed and validated in order to elucidate which compound is responsible for the pharmacological activity in vivo. Chromatographic separation of E-6087 was achieved using acetonitrile-phosphate buffer (pH 2.5; 25 mM) (60:40, volume/volume) as mobile phase and two 4.6x150 mmx5 µm Inertsil ODS-2 columns. For E-6132, two Inertsil ODS-3 columns and 52% of acetonitrile were used instead. Internal standards and fluorescence detection differed between both methods. The same online solid-phase extraction method was used. Mean retention times for E-6087 and E-6132 were 15.2 (±1.3) and 36.1 (±0.6) min, resp. The methods were selective and linear over the concentration range of 10-500 ng ml⁻¹ (r²≥0.996) for E-6087 and 5-200 ng ml⁻¹ (r²≥0.997) for E-6132. The limits of quantitation were 10 ng ml⁻¹ (E-6087) and 5 ng ml⁻¹ (E-6132) with a precision and accuracy <16% (E-6087) and <11% (E-6132). Mean recoveries from plasma were 43.2-61.9% (E-6087) and 60.4-65.2% (E-6132). For both compounds, both inter-assay and intra-assay precision and accuracy were within acceptable limits (<15%). As an example of the suitability of these methods, the results from a pharmacokinetic study are reported. After single oral administration of 5 mg kg⁻¹ of E-6087 to rats, plasma concentrations of E-6087 at peak time were higher than those of E-6132, suggesting that activity is mainly due to E-6087.
 IT 251442-94-1
 RL: ANT (Analyte): BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)
 (development and validation of two chromatographic methods for quantification of E-6087 and its metabolite, E-6132, in rat plasma)
 RN 251442-94-1 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)]-. (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:900446 CAPLUS
 DN 134:42125
 TI 1-(4-Sulfamylphenyl)-3-substituted-5-aryl-2-pyrazolines, method of preparation and use as inhibitors of cyclooxygenase-2
 IN Reddy, E. Premkumar; Reddy, M. V. Ramana
 PA Temple University - of the Commonwealth System of Higher Education, USA
 SO PCT Int. Appl., 38 pp.
 CODEN: PIIXDD
 DT Patent
 LA English
 FAN CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000/05603	A1	20001221	WO 2000-US16656	20000616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, NZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377153	AA	20001221	CA 2000-2377153	20000616
EP 1191931	A1	20020403	EP 2000-939946	20000616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6370519	B1	20020423	US 2000-595760	20000616
JP 200301464	T2	20030114	JP 2001-502836	20000616
NZ 516553	A	20040130	NZ 2000-516553	20000616
AU 771668	B2	20040401	AU 2000-54951	20000616
PRAI US 1999-139416P	P	19990616		
WO 2000-US16656	W	20000616		

OS MARPAT 134:42125
 AB 1-(4-Sulfamylphenyl)-3-X-5-2-pyrazolines (X = trihalomethyl, Cl-C6 alkyl, and C6H3R3R4 (R3, R4 = H, halogen, hydroxyl, nitro, Cl-C6 alkyl, Cl-C6 alkoxy, carboxy, Cl-C6 trihalomethyl, CN); Z = substituted and unsubstituted aryl) or a pharmaceutically acceptable salt thereof, a method of preparation and uses as inhibitors of cyclooxygenase-2 activity are claimed. They are useful for treating cyclooxygenase-mediated disorders, including, for example, inflammation, neoplastic disorders and angiogenesis-mediated disorders. The compounds of the invention preferably are characterized by a selectivity ratio for cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least approx.50, more preferably at least approx.100; data are reported for 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline and 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline. The claimed method of preparation comprises reacting trans-ZCH:CHC(O)X with 4-sulfamylphenylhydrazine or salt thereof.
 IT 71203-35-SP, 5-(4-Methoxyphenyl)-1-(4-sulfamylphenyl)-3-phenyl-2-pyrazoline 77121-23-4P, 1-(4-Sulfamylphenyl)-3-(4-chlorophenyl)-5-phenyl-2-pyrazoline 80883-92-7P, 3-(4-Methoxyphenyl)-1-(4-

L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


sulfamylphenyl)-5-phenyl-2-pyrazoline 122259-17-OP, 1-(4-Sulfamylphenyl)-3-(4-bromophenyl)-5-phenyl-2-pyrazoline 251442-96-3P, 1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline 313236-73-6P, 1-(4-Sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline 313236-74-7P, 1-(4-Sulfamylphenyl)-3,5-bis(4-fluorophenyl)-2-pyrazoline 313236-75-OP, 1-(4-Sulfamylphenyl)-5-(4-chlorophenyl)-3-(4-fluorophenyl)-2-pyrazoline 313236-76-9P, 5-(4-Tolyl)-1-(4-sulfamylphenyl)-3-(4-fluorophenyl)-2-pyrazoline 313236-77-OP, 1-(4-Sulfamylphenyl)-3,5-bis(4-chlorophenyl)-2-pyrazoline 313236-78-1P, 5-(4-(Methylthio)phenyl)-3-(4-tolyl)-1-(4-sulfamylphenyl)-2-pyrazoline 313236-79-2P, 5-(4-(Methylsulfonyl)phenyl)-3-(4-tolyl)-1-(4-sulfamylphenyl)-2-pyrazoline
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 1-(4-sulfamylphenyl)-3-substituted-5-aryl-2-pyrazolines useful as selective inhibitors of cyclooxygenase-2)

RN 71203-35-5 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)]-. (9CI) (CA INDEX NAME)



RN 77121-23-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-(4-chlorophenyl)-4,5-dihydro-5-phenyl-1H-pyrazol-1-yl)]-. (9CI) (CA INDEX NAME)




RN 80883-92-7 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)]-. (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 122259-17-0 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-bromophenyl)-4,5-dihydro-5-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251442-96-3 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 313236-73-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 313236-77-0 CAPLUS
 CN Benzenesulfonamide, 4-[3,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 313236-78-1 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(4-methylphenyl)-5-[4-(methylthio)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 313236-79-2 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(4-methylphenyl)-5-(4-


L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 313236-74-7 CAPLUS
 CN Benzenesulfonamide, 4-[3,5-bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 313236-75-8 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 313236-76-9 CAPLUS

L4 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:784081 CAPLUS

DN 132:12302

TI Diarylpyrazoles as inhibitors of cyclooxygenase-2

IN Gaberres-Altitent, Maria Rosa; Berrocal-Romero, Juana Maria;

Conti-Joch-Libet, Maria Montserrat; Frigola-Constans, Jordi

PA Laboratorios Del Esteve, S.A., Spain

SO PCT Int. Appl., 60 pp.

CODEN: PIXX02

DT Patent

LA Spanish

FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9962884	A1	19991209	WO 1999-ES156	19990527
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ES 2137138	A1	19991201	ES 1998-1129	19990529
ES 2137138	B1	20000916		
CA 2333475	AA	19991209	CA 1999-2333475	19990527
AU 9939329	A1	19991220	AU 1999-39329	19990527
AU 752001	B2	20020905		
EP 1083171	A1	20010314	EP 1999-922192	19990527
EP 1083171	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9910801	A	20011127	BR 1999-10801	19990527
SI 20580	C	20011231	SI 1999-20042	19990527
JP 2002516908	T2	20020611	JP 2000-552096	19990527
NZ 508990	A	20021220	NZ 1999-508990	19990527
TW 572898	B	20040121	TW 1999-88108709	19990527
AT 265437	E	20040515	AT 1999-922192	19990527
RU 2233272	C2	20040727	RU 2000-133231	19990527
PT 1083171	T	20040930	PT 1999-922192	19990527
NO 200006029	A	20010126	NO 2000-6029	20001128
LT 4879	B	20020125	LT 2000-108	20001128
US 6353117	B1	20020305	US 2000-701276	20001128
BG 105005	A	20010831	BG 2000-105005	20001129
ZA 2000007638	A	20011113	ZA 2000-7638	20001219
LV 12632	B	20010720	LV 2000-161	20001228
PRAI ES 1998-1129	A	19980529		
WO 1999-ES156	W	19990527		

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 251443-65-9P 251443-66-0P


RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylpyrazoles as inhibitors of cyclooxygenase-2)

RN 251443-65-9 CAPLUS

CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 251443-66-0 CAPLUS

CN Benzenesulfonamide, 4-[(5S)-5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 251443-24-0P 251443-31-9P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diarylpyrazoles as inhibitors of cyclooxygenase-2)


RN 251443-24-0 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(amino sulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

OS MARPAT 132:12302

GI



AB Diarylpyrazoles I (R1 = H, Me, CH2F, CHF2, CF3, CO2H, alkoxycarbonyl, carbamoyl, CN; R2 = H, Me; R3, R4, R7, R8 = H, Cl, F, Me, CF3, OMe; R5 = H, Cl, F, Me, CF3, OMe, OCF3, R6 = SO2Me, SO2NH2, SO2NHAc; R7 = SO2Me, SO2NH2, SO2NHAc, R8 = H, Cl, F, Me, CF3, OMe, OCF3) were prepared for use in treating inflammation and other processes mediated by COX-2. Thus, 2,4-F2C6H3CHO was treated with CF3CO2Me to give (E)-2,4-F2C6H3CH=OOCF3 which was cyclized with 4-H2NSO2C6H4NH2 to give I (R1 = CF3, R2-R4, R7, R8 = H, R5 = SO2Me, R6 = Me) which gave 92% inhibition of COX-2 activity at 40 mg/kg orally in rats.


IT 251442-94-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of diarylpyrazoles as inhibitors of cyclooxygenase-2)

RN 251442-94-1 CAPLUS

CN Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-31-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-[4-(amino sulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 123909-93-3P 251442-92-9P 251442-96-3P

251442-99-6P 251443-02-4P 251443-04-6P

251443-05-7P 251443-06-8P 251443-07-9P

251443-09-1P 251443-11-5P 251443-12-6P

251443-13-7P 251443-14-8P 251443-15-9P

251443-17-1P 251443-20-6P 251443-25-1P

251443-27-3P 251443-28-4P 251443-30-8P

251443-34-2P 251443-35-3P 251443-36-4P

251443-37-5P 251443-38-6P 251443-39-7P

251443-40-0P 251443-41-1P 251443-42-2P

251443-43-3P 251443-44-4P 251443-45-5P

251443-46-6P 251443-47-7P 251443-48-8P

251443-50-2P 251443-51-3P 251443-52-4P

251443-53-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylpyrazoles as inhibitors of cyclooxygenase-2)


RN 123909-93-3 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251442-92-9 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251442-96-3 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251442-99-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 251443-06-8 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-07-9 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-09-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-02-4 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-04-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-dichlorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-05-7 CAPLUS


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 251443-11-5 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 251443-12-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3-chloro-4-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-13-7 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-(trifluoromethoxy)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251443-14-8 CAPLUS
 CN Benzenesulfonamide, 4-[(2,3-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-15-9 CAPLUS
 CN Benzenesulfonamide, 4-[(2,4-dimethylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-(4-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 251443-28-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 251443-30-8 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 251443-34-2 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3,4-dimethylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251443-17-1 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(4-fluorophenyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 251443-20-6 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 251443-25-1 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 251443-27-3 CAPLUS


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-35-3 CAPLUS
 CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxy-3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 251443-36-4 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 251443-37-5 CAPLUS
 CN Benzenesulfonamide, 4-[(5-(2-fluoro-4-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-38-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2,4-dimethoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-39-7 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluoro-2-methoxyphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-40-0 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(2,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251443-43-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-[2-fluoro-4-(trifluoromethyl)phenyl]-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-44-4 CAPLUS
 CN Benzenesulfonamide, 4-[5-[2,4-bis(trifluoromethyl)phenyl]-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-45-5 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3-fluoro-2-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 251443-41-1 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(trifluoromethyl)-5-(2,3,4-trifluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-42-2 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-chloro-4-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 251443-46-6 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxy-2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 251443-47-7 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(2,4-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-48-8 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluoro-2-(trifluoromethyl)phenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-50-2 CAPLUS

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Benzenesulfonamide, 4-[5-(2-chlorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-51-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chloro-2-fluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 251443-52-4 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-fluoro-2-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 251443-53-5 CAPLUS
 CN Benzenesulfonamide, 4-[5-(2-fluoro-4-methylphenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:102309 CAPLUS
 DN 126:199491
 TI New pyrazoline and pyrazole derivatives
 AU Ankiwala, M. D.; Hathi, M. V.
 CS Chem. Dep., R. R. Mehta Coll. Sci., Palanpur, 385 002, India
 SO Journal of the Institution of Chemists (India) (1996), 68(4), 105-107
 CODEN: JOICA7; ISSN: 0020-3254
 PB Institution of Chemists (India)
 DT Journal
 LA English
 GI



AB Some new 2-pyrazolines I (R = 3,4-dichlorophenyl, 4-bromophenyl, 2-furyl, 2-hydroxy-3'-bromo-4'-butoxy-5'-nitrophenyl) have been prepared by the reaction of 2'-hydroxy-3'-bromo-4'-butoxy-5'-nitrophenol II with p-sulphamylphenylhydrazine hydrochloride. Mild oxidation of the pyrazolines with bromine water led to the formation of the corresponding pyrazoles III. The structures of the products have been characterized by IR and NMR spectral studies.


IT 187611-42-3P 187611-45-6P 187611-46-7P
 187611-47-8P 187611-48-9P 187611-49-0P
 187611-50-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazoles and pyrazolines)


RN 187611-42-3 CAPLUS

CN Benzenesulfonamide, 4-[3-(3-bromo-4-butoxy-2-hydroxy-5-nitrophenyl)-5-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 187611-45-6 CAPLUS
 CN Benzenesulfonamide, 4-[3-(3-bromo-4-butoxy-2-hydroxy-5-nitrophenyl)-5-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 187611-46-7 CAPLUS
 CN Benzenesulfonamide, 4-[3-(3-bromo-4-butoxy-2-hydroxy-5-nitrophenyl)-5-(2-furyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 187611-47-8 CAPLUS


CN Benzenesulfonamide, 4-[3-(4-butoxy-2-hydroxy-5-nitrophenyl)-5-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 187611-48-9 CAPLUS

CN Benzenesulfonamide, 4-[3-(4-butoxy-2-hydroxy-5-nitrophenyl)-4,5-dihydro-5-(2-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 187611-49-0 CAPLUS

CN Benzenesulfonamide, 4-[3-(4-butoxy-2-hydroxy-5-nitrophenyl)-4,5-dihydro-5-(2-hydroxyphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 187611-50-3 CAPLUS

CN Benzenesulfonamide, 4-[3-(4-butoxy-2-hydroxy-5-nitrophenyl)-5-(2-furyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:714395 CAPLUS

DN 126:47144

TI Synthesis of some hydrazone and pyrazoline derivatives

AU Faldallah, Hassan M.; Mokhtar, Hassan M.; Nassar, Ahmed; Ahmed, Mohamed M.

CS Faculty Science, University Alexandria, Alexandria, Egypt

SO Pakistan Journal of Scientific and Industrial Research (1995), 38(5-6), 179-181

CODEN: PSIRAA; ISSN: 0030-9985

PB Pakistan Council of Scientific and Industrial Research

DT Journal

LA English

AB Condensation of chalcones with arylhydrazines and arylhydrazines gave the corresponding hydrazones, and cyclization of the hydrazones with HCl gave pyrazoline derivs. which on oxidation with bromine water yielded the corresponding pyrazoles.

IT 184775-79-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyrazoline derivs. from chalcones and hydrazines)

RN 184775-79-9 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-bromophenyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



IT 184775-82-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrazoline derivs. from chalcones and hydrazines)

RN 184775-82-4 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-bromophenyl)-3-[2-(4-bromophenyl)ethenyl]-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 187611-43-4P 187611-44-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrazoles and pyrazolines)


RN 187611-43-4 CAPLUS

CN Benzenesulfonamide, 4-[3-(3-bromo-4-butoxy-2-hydroxy-5-nitrophenyl)-5-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 187611-44-5 CAPLUS


CN Benzenesulfonamide, 4-[3-(3-bromo-4-butoxy-2-hydroxy-5-nitrophenyl)-5-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:672022 CAPLUS
 DN 125:326590
 TI Synthesis and biological activity of new pyrazolines and pyrazoles
 AU Basaif, Saleh A.; Faldellah, Hassan M.; Hasan, Seham Y.
 CS Faculty Science, University King Abdulaziz, Jeddah, 21413, Saudi Arabia
 SO Indian Journal of Heterocyclic Chemistry (1996), 6(1), 53-58
 CODEN: IJOHE1; ISSN: 0971-1627
 PB Lucknow University, Dep. of Chemistry
 DT Journal
 LA English
 GI




AB Condensation of p-sulfonylphenylhydrazine with chalcones leads either to hydrazones or to pyrazolines I (R = H, R1 = Ph, p-tolyl, p-BrC6H4). Oxidation of I (R = H) afforded the corresponding pyrazole derivs. Benzenesulfonylureas and -thioureas I (R = CONHR2 or CSNHR2 (R2 = Ph, cyclohexyl, 1-naphthyl, PhCH2)) were also prepared. Cyclization of the thiourea group of compds. I (R = CSNHR2) by treating with Et bromoacetate, Et β -bromopropionate, or d-bromocetophenone afforded the corresponding thiazolidinone, thiazinone and thiazoline derivs., resp. The synthesized compds. showed no antibacterial or antifungal activities.


II 183243-05-2P 183243-06-3P 183243-07-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and biol. activity of new pyrazolines and pyrazoles)

RN 183243-05-2 CAPLUS
 CN Benzenesulfonylamide, 4-[5-(9-anthracenyl)-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 183243-06-3 CAPLUS
 CN Benzenesulfonylamide, 4-[5-(9-anthracenyl)-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 183243-07-4 CAPLUS
 CN Benzenesulfonylamide, 4-[5-(9-anthracenyl)-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:426767 CAPLUS
 DN 125:142626
 TI Synthesis and spectral studies of some new pyrazolines and pyrazoles
 AU El Sadek, M. M.; Faldellah, H. M.; El Socary, Nagwa N.; Hassan, Seham Y.
 CS Faculty Science, Alexandria University, Alexandria, Egypt
 SO Egyptian Journal of Chemistry (1995), 38(4), 403-418
 CODEN: EGJCA3; ISSN: 0367-0422
 PB National Information and Documentation Centre
 DT Journal
 LA English
 GI




AB A number of 3'-(3-aryl-2-methylpyrrol-5-yl)-1'-aryl-2'-propen-1'-ones I (R = Ar = Ph, R1 = H, X = O; R = OEt, R1 = Me, Ar = 4-BrC6H4, X = O; R = OEt, R1 = H, Ar = Ph, 4-ClC6H4, 4-BrC6H4, 4-MeC6H4, 4-MeOC6H4, 4-HOCC6H4, 4-H2NCC6H4, 4-O2NCC6H4, X = O) have been prepared and transformed into the corresponding arylhydrazones I (X = NNHC6H4R2, R2 = H, 4-NO2, 2,4-(NO2)2). These hydrazones were cyclized to the pyrazolines II, which were oxidized to the corresponding pyrazoles. In addition, heating of the pyrazoline II (R = EtO, R1 = Me, R2 = H, Ar = 4-BrC6H4) with hydrazine hydrate afforded the hydrazide II (R = NNH2, R1 = Me, R2 = H, Ar = 4-BrC6H4) while pyrazolines II [R = EtO, R1 = H, R2 = 2,4-(O2N)2, Ar = 4-H2NCC6H4; R = EtO, R1 = Me, R2 = H, Ar = 4-BrC6H4] gave the acids II [R = OH, R1 = H, R2 = 2,4-(O2N)2, Ar = 4-H2NCC6H4; R = OH, R1 = Me, R2 = H, Ar = 4-BrC6H4] upon hydrolysis. Spectral properties of the prepared compds. were discussed.

II 179636-04-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis and spectral studies of some new pyrazolines and pyrazoles)

RN 179636-04-5 CAPLUS
 CN Benzenesulfonylamide, 4-[5-(4-benzoyl-5-methyl-1H-pyrrol-2-yl)-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:122148 CAPLUS

DN 124:289336

TI Synthesis of new pyrazoline and pyrazole derivatives

AU Basaif, Salem A.; Albar, Hassan A.; Faldallah, Hassan M.

CS Faculty Science, King Abdulaziz University, Jeddah, Saudi Arabia

SO Indian Journal of Heterocyclic Chemistry (1995), 5(2), 121-4

CODEN: IJCHEI; ISSN: 0971-1627

PB Lucknow University, Dep. of Chemistry

DT Journal

LA English

AB Condensation of p-sulfamylphenylhydrazine with chalcones, leads either to hydrazones or pyrazolines which were oxidized to pyrazoles.

Benzenesulfonylureas and thioureas were also prepared, and the thioureas were converted to the corresponding thiazolidinones on reaction with Et bromoacetate.


IT 175654-05-4P 175654-06-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reactions of)

RN 175654-05-4 CAPLUS

CN Benzenesulfonamide, 4-[5-(1,3-benzodioxol-5-yl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 175654-06-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(1,3-benzodioxol-5-yl)-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



L4 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:534017 CAPLUS

DN 121:134017

TI Pyrazole derivatives. Part I. Synthesis and spectra of trisubstituted pyrazoline and pyrazole derivatives with possible hypoglycemic activity

AU Makki, Mohamed S. I.; Faldallah, Hassan M.

CS Fac. Sci., Univ. King Abdul Aziz, Saudi Arabia


SO International Journal of Chemistry (1993), 4(4), 117-28

CODEN: INJCEW

DT Journal

LA English

GI



AB Condensation of chalcones with arylhydrazines leads either to hydrazones or pyrazolines, e.g. I, depending on the condition of the reaction.

Oxidation of the pyrazolines with bromine water affords pyrazole derivs.

Reaction of the pyrazolines and pyrazoles with isocyanate and

isothiocyanate derivs. leads to the corresponding ureas and thioureas,

resp. Cyclization of the thioureas with Et bromoacetate and Et

bromopropionate affords thiazolidinones and thiazinones, resp.


IT 156849-08-0P 156885-17-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 156849-08-0 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-3-(4-methoxyphenyl)-5-(2-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 156885-17-5 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-3-phenyl-5-(2-thienyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



L4 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STM
 AN 1993:671065 CAPLUS
 DN 119:271065
 TI Triazole-pyrazole compounds with possible biological activity. Part-II
 AU Mokhtar, Hassan M.; Faldallah, Hassan M.; Moustafa, Jehan M.
 CS Fac. Sci., Univ. Alexandria, Alexandria, Egypt
 SO Pakistan Journal of Scientific and Industrial Research (1992), 35(11),
 428-33
 CODEN: PSIRAA; ISSN: 0030-9885
 DT Journal
 LA English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensation of 4-formyl-2-aryl-1,2,3-triazoles with acetophenones gave chalcones which were treated with hydrazines to give the corresponding hydrazones or pyrazolines. Condensation reaction of (phenyltriazolyl)(aminosulfonyl)pyrazolidines I (X = halo; Y = halo, aminosulfonyl, alkyl, etc.) with isothiocyanates followed condensation with bromoacetate gave the thiazolidinones II (same X, Y; R = alkyl, aryl).

IT 150981-69-4P 150981-72-9P 150981-74-1P


150981-77-4P 150981-78-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 150981-69-4 CAPLUS


CN Benzenesulfonyl amide, 4-[5-[2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl]-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 150981-72-9 CAPLUS


CN Benzenesulfonyl amide, 4-[3-(4-chlorophenyl)-5-(2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STM (Continued)




RN 150981-78-5 CAPLUS

CN Benzenesulfonyl amide, 4-[5-[2-(4-bromophenyl)-2H-1,2,3-triazol-4-yl]-4,5-dihydro-3-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STM (Continued)



RN 150981-74-1 CAPLUS

CN Benzenesulfonyl amide, 4-[5-[2-(4-bromophenyl)-2H-1,2,3-triazol-4-yl]-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 150981-77-4 CAPLUS

CN Benzenesulfonyl amide, 4-[3-(4-bromophenyl)-5-(2-(4-bromophenyl)-2H-1,2,3-triazol-4-yl)-4,5-dihydro-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2005 ACS ON STM

AN 1993:603346 CAPLUS

DN 119:203346

TI Triazole-pyrazole compounds with possible biological activity. Part-I.

Synthesis and spectra

AU Faldallah, Hassan M.; Mokhtar, Hassan M.; Moustafa, Jehan M.;

Kuzmerikiewicz, Wojciech

CS Fac. Sci., Univ. Alexandria, Alexandria, Egypt

SO Pakistan Journal of Scientific and Industrial Research (1992), 35(6),

213-20

CODEN: PSIRAA; ISSN: 0030-9885

DT Journal

LA English

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensation of aryl(aryl)triazolyl)propenones I (R = H, Me, Cl, Br) with 4-R1C6H4NNH2 (R1 = H, Me, Cl, NO2, SO2NH2, NO2, SO2NH2) leads either to hydrazones II or pyrazolines III depending upon the reaction conditions. Treatment of III with Br2 in H2O affords bromopyrazoles IV. Reaction of III and IV (R = H, Br; R1 = SO2NH2) with R2NCS (R2 = Bu, Ph, benzyl, allyl) gave the corresponding thioureas III and IV (R1 = SO2NHCSNR2). Cyclocondensation of III (R = Br, R1 = SO2NHCSNR2; R2 = allyl, Ph) and IV (R = H, Br; R1 = SO2NHCSNR2; R2 = allyl, Ph) with BrCH2CO2Et in EtOH gave thiazolidinone derivs. V and VI.


IT 148649-34-7P 148649-42-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and bromination-dehydrogenation and reaction of, with isothiocyanates)

RN 148649-34-7 CAPLUS


CN Benzenesulfonyl amide, 4-[4,5-dihydro-3-phenyl-5-(2-phenyl-2H-1,2,3-triazol-4-yl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 148649-42-7 CAPLUS

CN Benzenesulfonyl amide, 4-[3-(4-bromophenyl)-4,5-dihydro-5-(2-phenyl-2H-1,2,3-triazol-4-yl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 148649-36-9P 148649-38-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and bromination-dehydrogenation of)

RN 148649-36-9 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methylphenyl)-5-(2-phenyl-2H-1,2,3-triazol-4-yl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



RN 148649-38-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-(4-chlorophenyl)-4,5-dihydro-5-(2-phenyl-2H-1,2,3-triazol-4-yl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:591744 CAPLUS

DN 117:191744

TI Trisubstituted pyrazoles of possible hypoglycemic activity

AU Faldallah, H. M.; El Sadek, Mohamed M.; El-Massry, A. M. I.; Hassan, Sahar Y.

CS Fac. Sci., Alexandria Univ., Alexandria, Egypt

SO Pakistan Journal of Scientific and Industrial Research (1992). 35(1-2).


8-13

CODEN: PSIRAA; ISSN: 0030-9885

DT Journal

LA English

GI



AB Cyclocondensation of 4-H₂N₂O₂C₆H₄NHNH₂ with chalcones RCOCH:CH₂ (R = 4-MeOC₆H₄, 4-MeC₆H₄, R1 = 4-MeOC₆H₄, 4-MeC₆H₄) gave diaryldihydropyrazoles I (R2 = H) in 42-82% yields. Mild oxidation of I with bromine water gave pyrazoles II (R2 = H), while condensation of I and II (R2 = H) with isocyanates and isothiocyanates gave I and II (R2 = CONHPh, CONH₂Et, CONHC₆H₁₁, CSNHPh, CSNHCH₂CH₂CH₂). Cyclocondensation of I (R = R1 = 4-MeC₆H₄, R2 = CSNHPh) with BrCH₂CO₂Et gave thiazolidinone III (n = 1), while condensation of I (R = 4-MeOC₆H₄, R1 = 4-MeOC₆H₄, R2 = CSNHPh) with BrCH₂CO₂Et gave dihydrothiazinone III (n = 2).

IT 80883-93-8P 143809-35-2P 143809-36-3P

143809-37-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, dehydrogenation, and addition reactions of, with isocyanates and isothiocyanates)


RN 80883-93-8 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 143809-35-2 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 143809-36-3 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methoxyphenyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 143809-37-4 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methoxyphenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:409795 CAPLUS
 DN 117:9795
 TI Electronic nature of polyfluoroalkoxysulfonyl groups and their effect on spectral characteristics of azo and triarylpyrazoline dyes
 AU Popov, V. I.; Skripkina, V. T.; Protayk, S. P.; Skrynnikova, A. A.; Krasovitskii, B. M.; Yagupol'skii, L. M.
 CS Inst. Org. Khim., Kiev, USSR
 SO Ukrain'skii Khimicheskii Zhurnal (Russian Edition) (1991), 57(8), 843-9
 CODEN: UKZHAU; ISSN: 0041-6045
 DT Journal
 LA Russian
 AB The electron-acceptor nature of polyfluoroalkoxysulfonyl groups was comparable to that of a HCF₂SO₂ group. The similarity of the electron nature of these groups was supported by the similarity of their influence on the spectral properties of azo and triarylpyrazoline dyes. The polyfluoroalkoxysulfonyl groups exhibited high sensitivity in aromatic nucleophilic substitution reactions. Substituent consts. were determined for RSO₂ groups (R = alkyl, fluoroalkyl) in meta- and para-substituted fluorobenzene. Spectral data and phys. consts. are given for polyfluoroalkoxysulfonyl-substituted benzenes and triarylpyrazolines.
 IT 141795-69-9
 RL: USES (Uses)
 (dye, spectral properties of, effect of polyfluoroalkoxysulfonyl groups on)
 RN 141795-69-9 CAPLUS
 CN Benzenesulfonic acid, 4-[1-[4-(aminosulfonyl)phenyl]-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl]-, 2,2,3,3-tetrafluoropropyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:255606 CAPLUS
 DN 116:255606
 TI Preparation of phenylpyrazole derivatives as additives for photosensitive resins or their base materials
 IN Furuta, Yasushi; Tamura, Yoshisada
 PA Nippon Chemical Works Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKCXAF
 DT Patent
 LA Japanese
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03284668	A2	19911216	JP 1990-81048	19900330
JP 2757528	B2	19980525		
PRI/JP 1990-81048		19900330		


OS MARPAT 116:255606
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Phenylpyrazole derivs. [I, II: A = H, (R₂)nCGH_{5-n} wherein R₂ = H, halo, (substituted) alkyl, etc., n = 1-3; B = O, Q1 wherein R₃, R₄ = H, alkyl; X = O, (alkyl)imino; Y = H, Ph, alkyl- or alkoxyphenyl; Z = O, S, (alkyl)imino; R₁ = H, halo, (substituted) alkyl, etc.; m = 1-3; 1 = O, 1; R₇, R₈ = H, halo, (substituted) alkyl, etc.] are prepared. Diazotization of amine compound III (R = H) followed by reduction with SnCl₂ gave hydrazine III (R = NH₂), which was refluxed with chalcone and NaOAc in HOAc to give 77.6% pyrazoline derivative I (A = Ph, R₁ = H, 1 = O, B = Q wherein X = NH, Y = Ph, R₃ = H), which was incorporated into a photosensitive solution for a photosensitive element in a photoresist giving a high resolution pattern.
 IT 141391-64-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as additive for photosensitive resins)
 RN 141391-64-2 CAPLUS
 CN Benzenesulfonamide, 4,4'-[1-[(phenylethynylidene)bis(4,5-dihydro-5-phenyl-1H-pyrazole-3,1-diy)]bis- (9CI) (CA INDEX NAME)




L4 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:6480 CAPLUS
 DN 116:6480
 TI Synthesis of nitrogenous compounds. Part III
 AU Mokhtar, H. M.; Farahat, O. O.
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SO Pakistan Journal of Scientific and Industrial Research (1991), 34(1), 9-15
 CODEN: PSIRAA; ISSN: 0030-9885
 DT Journal
 LA English
 GI




AB Condensation of formyltriazole I with hydrazines gave hydrazones which were subsequently transformed into triazolyloxadiazoles, -pyrazolines, -iminothiazolidinones, and -iminothiazinones.
 IT 137272-40-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and oxidative bromination or addition reaction of, with isocyanates)
 RN 137272-40-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-[2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl]-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:207194 CAPLUS
 DN 114:207194
 TI Synthesis of nitrogenous compounds. Part II
 AU Mokhtar, Hassan M.
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SO Pakistan Journal of Scientific and Industrial Research (1990), 33(1-2), 30-6
 CODEN: PSIRAA; ISSN: 0030-9885
 DT Journal
 LA English
 OS CASREACT 114:207194
 AB 2,4-Dioxohexenoates have been prepared by the condensation of ketones with Et oxalate and converted to isoxazole, pyrazole, and quinoxaline derivs. for the study of structure activity relationship. A number of trisubstituted pyrazoles have been synthesized to study their potential use as antimicrobial and/or hypoglycemic agents.
 IT 130953-84-3P 130953-88-7P 133506-68-0P
 RL SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 130953-84-3 CAPLUS
 CN Benzenesulfonamide, 4-[5-(3-chlorophenyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 130953-88-7 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(3-nitrophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:632651 CAPLUS
 DN 111:232651
 TI Synthesis of nitrogenous compounds from 8-unsaturated 1,3-dicarbonyl esters. Part I. Substituted pyrazoles, isoxazoles, and oxyquinoxalines
 AU Mokhtar, Hassan M.
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SO Journal of the Chemical Society of Pakistan (1988), 10(4), 414-24
 CODEN: JCSPOF; ISSN: 0253-5106
 DT Journal
 LA English
 OS CASREACT 111:232651
 GI




AB Condensation of 4-RC6H4CH=CHCO2Me (I; R = Me, Cl) with Et oxalate gave 4-RC6H4CH=CHCO2CH2CO2Et (II), which were converted to the Me esters by alcoholysis. II were converted by hydrazine or arylhydrazine into the corresponding Et pyrazole-3-carboxylates III (X = NR1; R = Me, Cl; R1 = H, Ph, 4-C6H4SO2NH2, 4-C6H4Cl, 4-C6H4NO2, etc.), which were hydrolyzed to the acids. With hydroxylamine, II afforded isoxazoles III (X = O), whereas, with o-phenylenediamine they gave oxyquinoxaline derivs. IV. II on reaction with acylhydrazines gave the acylhydrazones which were cyclized to the corresponding N-acylpyrazoles III (X = NCO2R; R = Me, Cl, R2 = Ph, 4-ClC6H4). Reaction of I with arylhydrazines afforded the corresponding hydrazones which on boiling with ethanol containing two drops of HCl underwent cyclization to pyrazolines.
 IT 123909-96-6P
 RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and bromination of)
 RN 123909-96-6 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 133506-68-0 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 123909-90-0P 123909-93-3P
 RL SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 123909-90-0 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(2-methoxyphenyl)-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 123909-93-3 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:515095 CAPLUS
 DN 111:115095
 TI Pyrazole derivatives with possible hypoglycemic activity
 AU Faid-Allah, Hassan M.; Mokhtar, Hassan M.
 CS Fac. Sci., Univ. Alexandria, Alexandria, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1988), 27B(3), 245-9
 CODEN: IJSCOB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 111:115095
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensation reaction of p-HNSO₂CGH₄NNH₂.HCl with p-RCGH₄CH:CHCOGHR₁-1-p
 (R = H, R₁ = OMe, Cl, Br, NH₂; R = MeO, R₁ = H) gave the corresponding
 hydrazones in the presence of NaOAc. In the absence of NaOAc, the products
 were pyrazolines I (R₂ = H). Oxidation of I with Br gave pyrazoles II (R₂ =
 H). Acylation and thioacylation of I and II with Br₂COX (R₃ = Pr, Bu, Ph,
 cyclohexyl, X = O; R₃ = allyl, Ph, cyclohexyl, PhCH₂, X = S) gave ureas
 and thioureas I and II (R₂ = CONHR₃). Cyclocondensation of II (R₂ =
 CONHR₃) with Br(CH₂)_nCO₂Et (n = 1,2) gave imino heterocycles III.

IT 71203-35-5P 80883-92-7P
 RL: SPN (Synthetic preparation): PREP (Preparation)
 (preparation, oxidation, acylation, and thioacylation of)
 RN 71203-35-5 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-
 1-yl]- (9CI) (CA INDEX NAME)



RN 80883-92-7 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-
 1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1988:550699 CAPLUS
 DN 109:150699
 TI 1-(4-Sulfamylphenyl)-3-(4-fluorosulfonylphenyl)-5-phenyl-2-pyrazoline as
 a blue-green luminescent agent for polyethylene
 IN Krasovitskii, B. M.; Sal'vitskaya, L. N.; Skripkina, V. T.; Pereyaslova,
 D. G.; Chumak, T. V.; Andreeva, L. P.; Serdechnaya, T. A.
 PA USSR
 SO U.S.S.R.
 From: Otkrytiya, Izobret. 1988, (1), 76.
 CODEN: UROOAF
 DT Patent
 LA Russian
 FAN.CIT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1364622	A1	19880107	SU 1985-3963018	19851008
PRAI SU 1985-3963018		19851008		


AB The title compound (I) is used (2.08-4.16 g) in luminescent comps. giving
 good brightness and strong luminescence, containing phthalocyanine green
 0.50-1.50, 4-amino-N-phenylphthalamic acid 0.83-1.66, p-MeC₆H₄SO₂NH₂
 43.96-45.58, melamine 8.49-8.80, (NaO)2P(O)OH 0.25-0.26%, and formalin.

IT 116919-50-7
 RL: USES (Uses)
 (luminescent agent, in coloring of polyethylene)

RN 116919-50-7 CAPLUS
 CN Benzenesulfonyl fluoride, 4-[1-(4-amino sulfonylphenyl)-4,5-dihydro-5-
 phenyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 77121-23-4P 122259-17-0P
 RL: RCT (Reactant): SPN (Synthetic preparation): PREP (Preparation): RACT
 (Reactant or reagent)
 (preparation, oxidation, and acylation of, with isocyanates)


RN 77121-23-4 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-chlorophenyl)-4,5-dihydro-5-phenyl-1H-pyrazol-
 1-yl]- (9CI) (CA INDEX NAME)



RN 122259-17-0 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-bromophenyl)-4,5-dihydro-5-phenyl-1H-pyrazol-
 1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:628455 CAPLUS
 DN 107:228455
 TI Preparation and antidiabetic activity of new substituted
 3,5-diarylpyrazolesulfonylurea derivatives. II: Structure-activity
 relationship
 AU Soliman, Raefat; Faid-Allah, Hassan M.; El Sadeh, Samir K.
 CS Coll. Pharm., Univ. Alexandria, Alexandria, Egypt
 SO Journal of Pharmaceutical Sciences (1987), 76(8), 626-32
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 OS CASREACT 107:228455
 GI




I. 4, 5-satd.
 II. 4, 5-unsatd.

AB I [R = e.g., Me(CH₂)₂, cyclohexyl, Ph, Me(CH₂)₃, X = O or S, Y = H, Cl, Br
 or Me, Z = H or Me] were prepared by the condensation of appropriate
 chalcones with p-sulfamylphenylhydrazine followed by the reaction with
 isocyanates or isothiocyanates. II [R = e.g., Me(CH₂)₂, cyclohexyl, Ph, Y
 = O or S, Y = H, Cl, Br or Me, and Z = H or Me] were prepared by the oxidation
 of the appropriate 1-(p-sulfamylphenyl)-3,5-diaryl-2-pyrazolines with Br
 water followed by reaction with isothiocyanates or isocyanates. II (X =
 O) showed marked hypoglycemic activity at 100 mg/kg in rats, and their
 potency was greater than that of phenformin (pos. control). The pyrazoles
 were more active than pyrazolines. Structure-activity relations are
 discussed.


IT 111607-57-9P 111607-58-0P 111607-59-1P
 111607-60-4P
 RL: SPN (Synthetic preparation): PREP (Preparation)
 (preparation and dehydrogenation or reaction with isothiocyanates or
 isocyanates)

RN 111607-57-9 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methylphenyl)-3-phenyl-1H-pyrazol-
 1-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 111607-58-0 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 111607-59-1 CAPLUS
 CN Benzenesulfonamide, 4-[5-(4-bromophenyl)-4,5-dihydro-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 111607-60-4 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-3-(4-methylphenyl)-5-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:148807 CAPLUS

DN 104:148807

TI Synthesis of trisubstituted pyrazoles with possible antimicrobial activity

AU Mokhtar, Hassan M.

CS Fac. Sci., Univ. Alexandria, Alexandria, Egypt

SO Pakistan Journal of Scientific and Industrial Research (1985), 28(2),

85-91



CODEN: PSIRAA; ISSN: 0030-9885

DT Journal

LA English

GI

L4 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Condensation of formyltriazole I, prepared from D-arabino-hexose phenylisotriazole, with Me2CO gave unsatd. ketone II (R = COMe) (III) which was condensed with EtO2CCO2Et to give IV (R = OCH2CO2Et) followed by cyclocondensation with hydrazine to give pyrazoles IV (R1 = H, Ph, substituted Ph, 2-pyridyl, cinnolin-1-yl). Condensation of III with hydrazines gave V which underwent cyclization to give pyrazolines VI (R1 = Ph, substituted Ph, 2-pyridyl).

II 100568-26-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 100568-26-1 CAPLUS

CN Benzenesulfonamide, 4-[4,5-dihydro-3-methyl-5-(2-phenyl-2H-1,2,3-triazol-4-yl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:104140 CAPLUS
 DN 96:104140
 TI Trisubstituted pyrazoles of possible antidiabetic and antibacterial activity

AU Feld-Allah, Hassan M.
 CS Chem. Dep., Fac. Sci., Alexandria, Egypt
 SO Pharmazie (1981), 36(11), 754-6
 CODEN: PHARAT; ISSN: 0031-7144

DT Journal
 LA English


AB Condensation of benzalacetone and dibenzalacetone with 4-H₂NSO₂C₆H₄NH₂ (I) and 2-pyridylhydrazine led to the corresponding hydrazones. These were readily cyclized to pyrazolines on heating with HCl. The reaction of substituted benzalacetophenones with I and 2-pyridylhydrazine gave the pyrazoline derivs. directly. Oxidation of the pyrazolines with Br-H₂O afforded the pyrazoles. Reaction of epoxy-p-methoxybenzalacetophenone with I gave a hydroxypyrazoline which oxidized to the hydroxypyrazole with Br-H₂O. Condensation of acylhydrazines with substituted benzalacetophenones afforded the corresponding acylhydrazones.

IT 10179-57-4P 71203-35-5P 80883-90-5P
 80883-91-6P 80883-92-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and oxidation of)


RN 10179-57-4 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-di(phenyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 71203-35-5 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(prepn. of)

RN 80883-93-8 CAPLUS


CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 80883-90-5 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-methyl-5-phenyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 80883-91-6 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-5-phenyl-3-(2-phenylethyl)-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 80883-92-7 CAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-3-(4-methoxyphenyl)-5-phenyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



IT 80883-93-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1981:140571 CAPLUS

DN 94:140571

TI Coloring of polyethylene by blue daytime fluorescent pigments

AU Sal'vitskaya, L. N.; Nesterkina, I. G.; Chumak, T. V.

CS Vses. Nauchno-Issled. Inst. Monokristal., Kharkov, USSR

SO Khimicheskaya Promyshlennost, Seriya: Proizvodstvo i Pererabotka


Plastmass i Sinteticheskikh Smol (1980), (7), 18-20

CODEN: KPSSDO; ISSN: 0131-5439

DT Journal

LA Russian

GI



AB Colored polyethylene [9002-88-4] parts with increased brightness and migration resistance of daylight fluorescent pigments are prepared using pyrazoline derivative I bonded with melamine toluenesulfonamide derivative-HCHO copolymer as luminophor and phthalocyanine blue [147-14-8] as pigment. The polymer in granular form was colored with pigments containing 1.0 and 2.0% luminophor by molding at 210° using 0.2% vaseline oil as wetting agent. The pigments were uniformly distributed in the polymer.


IT 77121-23-40, reaction products with melamine toluenesulfonamide derivative-formaldehyde polymers

RL: USES (Uses)


(daylight fluorescent pigments, for polyethylene)

RN 77121-23-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-(4-chlorophenyl)-4,5-dihydro-5-phenyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:524849 CAPLUS
 DN 91:124849
 TI Organic luminophors of the pyrazoline series - luminescent constituents of fluorescent pigments
 AU Pereyaslova, D. G.; Bondarenko, V. E.; Skripkina, V. T.; Vinetskaya, Yu. M.; Bogdanova, L. I.
 CS Nauchno-Proiz. Ob'edin. "Monokristallreaktiv", USSR
 SO Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1979), 45(6), 553-6
 CODEN: UKZHAU; ISSN: 0041-6045
 DT Journal
 LA Russian
 GI



AB The addition of 3-(4-difluoromethylsulfonylphenyl)-1,5-diphenyl-4,2-pyrazoline (I) [61102-38-3] to aminosulfonyltoluene-formaldehyde-melamine copolymer (II) [39277-28-6] gave a bright yellow fluorescent pigment with strong light absorption at 564 nm. When I and Rhodamine 5 [12627-64-4] were added to II the resulting orange-red pigment absorbed strongly at 609 nm. Similarly, a green fluorescent pigment was obtained by adding 1,4-bis[1,5-diphenyl-4,2-3-pyrazolyl]benzene [71203-34-4] and Direct Lightfast Turquoise K [50642-57-4] to II. Other shades of pigments were prepared by adding 1-(4-difluoromethylsulfonylphenyl)-3,5-diphenyl-4,2-pyrazoline [61102-37-2], or pyrazoline sulfonate III, X = H, H₂NSO₂, or Cl₂HSOCONHSO₂ (IV) to II. The synthesis of III (X = H) or III (X = H₂NSO₂) involved reacting sulfonated 4-methoxybenzalacetophenone with PhN:NH [100-63-0] or 4-H₂NSO₂CG₄NH [4392-54-5], resp. Refluxing III (X = H₂NSO₂) with stearic chloride [112-76-5] gave IV.
 IT 71203-35-50, sodium sulfonate salt.
 RL: USES (Uses)

L4 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1973:406798 CAPLUS
 DN 79:6798
 TI 3-(3',4'-Dichloro-6'-alkylphenyl)-2-pyrazoline derivatives as fluorescent whiteners
 IN Mengler, Helmut
 PA Farbwerke Hoechst A.-G.
 SO Ger. Offen., 29 pp. Addn. to Ger. Offen. 2,011,552 (CA 76:87172y).
 CODEN: GW00BX
 DT Patent
 LA German
 FAN_CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2145019	A1	19730322	DE 1971-2145019	19710909
NL 7212025	A	19730313	NL 1972-12025	19720904
BR 7206154	A0	19730925	BR 1972-6164	19720906
CH 7213074	A4	19760715	CH 1972-13074	19720906
CH 585728	A	19770315	CH 1975-3060	19720906
US 3865816	A	19750211	US 1972-287075	19720907
IT 1006044	A	19760930	IT 1972-28922	19720907
JP 48036476	A2	19730529	JP 1972-69641	19720908
CA 994774	A1	19760810	CA 1972-151239	19720911
BE 788658	A4	19730312	BE 1972-121892	19720911
FR 2155268	A6	19730518	FR 1972-32090	19720911
GB 1404037	A	19750828	GB 1972-42162	19720911
US 3957815	A	19760518	US 1974-483355	19740626
US 4045169	A	19770830	US 1976-658881	19760218
PRAI BE 1971-764127	A	19710311		
DE 1971-2145019	A	19710909		
US 1972-287075	A3	19720907		
US 1974-483355	A3	19740626		

AB Fluorescent whiteners (I, R = Me, Et; R₁ = H, o-NO₂SC₆H₄, p-MeOC₆H₄; R₂ = H, CF₃; R₃ = H, Cl, SO₂NH₂, SO₃Na, ON, alkylsulfonyl, alkylsulfamoyl, alkoxy-carbonyl, carboxy; R₄ = H, Cl, CF₃) were prepared and were used as whitening agents in textile wash baths and incorporation into polyacrylonitrile before spinning to fibers. Thus, 3,4,6-trimethoxy-2-oxo-2-(4-chlorophenyl)-1,2,3,4-tetrahydropyrazole was condensed with p-HO₂SC₆H₄NH₂ to give fluorescent whitener I (R = Me; R₁ = R₂ = R₄ = H, R₃ = SO₃Na) [40453-21-2]. The other I were similarly prepared.


IT 42803-39-4P 42803-41-8P
 RL: IMF (Industrial manufacture); PREP (Preparation) (preparation of)

RN 42803-39-4 CAPLUS
 CN Benzenesulfonic acid, 2-[1-[4-(aminosulfonyl)phenyl]-3-(4,5-dichloro-2-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-, monosodium salt (9CI) (CA INDEX NAME)


L4 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (luminophors, for fluorescent pigments contg. aminosulfonyltoluene-formaldehyde-melamine copolymer)
 RN 71203-35-5 CAPLUS
 CN Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 42803-41-8 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4,5-dichloro-2-methylphenyl)-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




LA ANSWER 37 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1966; 473994 CAPLUS
DN 65:7394
ORF 65:13850a-f
TI Fluorescent brighteners for synthetic fibers. XI. 2-Pyrazoline fluorescent
brightening agents containing pyridine rings
AU Maruyama, Takehito; Kawai, Masamichi; Kuroki, Nobuhiko; Konishi, Kenzo
CU Univ. Prefect., Osaka, Japan
SO Kogyo Kagaku Zasshi (1966), 69(1), 86-90
CODEN: KGGZAT; ISSN: 0368-5462
DT Journal
LA Japanese
GI For diagram(s), see printed CA Issue.
AB cf. preceding abstrs. Comps. of the general formula I were prepared and the
absorption and fluorescence spectra in EtOH and dioxane, brightening
effect, lightfastness, and dyeability on polyester, polypropylene,
polyamide, and acetate fibers were examined. Thus, a mixture of 4.5 g. styryl
2-methyl-5-pyridyl ketone, 3.2 g. p-MeC₆H₄NHNH₂.HCl and 21 cc. AcOH was
heated at 100-10° for 5 hrs. with stirring, poured onto ice water,
neutralized with aqueous Na2CO3 solution, extracted with AcOMe, dried over Na2SO4,
and the solvent removed to give 2.6 g. I (R¹ = Me, R² = H), yellow
crystals, m. 149-50° (MeOH), purified by chromatography on Al2O3
(C6H6). Similarly other I were prepared (R¹, R², % yield, m.p., and
λ_{max} in mμ (ε × 10⁻⁴) given): H, 88,
163-4°, 245(1.47) and 369(1.95); H, 88, 154-5°,
241(1.28) and 374(1.96); H, OMc, 96, 138-9°, 239.5(2.04), and
373(1.95); H, Cl, 67, 150-1°, 223.5(1.90), 243.5(1.93), and
370(2.01); H, Br, 96, 154-5°, 230(2.15) and 370(2.01); Me, H, 40,
149-50°, 245.5(1.61) and 370(1.85); Me, 64, 172-3°,
248(1.62) and 376(1.84); CO₂H, H, 98, 236-7°, 243(1.26), 281(1.25),
and 375(2.63); CO₂Me, H, 212-3°, 243 (1.23), 297(1.13), and
374(3.67); SO₂NH₂, H, 251-2°, 237 (1.27), 274(1.33), and 366(2.95).
In order to study the relationship between the structure of pyrazoline
derivs. and fluorescence spectra, several 1,3,5-triphenyl-2-pyrazoline
derivs. of the general formula II were also prepared. Thus, a mixture of 7.1
g. p-ACH₃CO₂CH₂.C6H₅, 3.2 g. PhNHNH₂, and 40 cc. AcOH was stirred at
30° for 20 hrs. and at 70° for 2 hrs., cooled, filtered,
and the residue washed with H₂O to give 7 g. II (X = H, Y = NHAc), pale yellow
crystals, m. 189-90° (EtOH)(chromatography on Al2O3). Similarly
prepared were the following II (X, Y, m.p., λ_{max} in mμ, and
ε × 10⁻⁴ given): AcNH, H, 203-5°, 373, 1.94; AcNH,
189-90°, 362, 1.78; Me, H, EtNC₆H₄CO₂H, 367, 1.89; H, NH₂,
178-84°, 362, 2.83; H, EtNC₆H₄CONH₂, 182-3°, 360, 2.22;
MeOC, H, 193.5-4.5°, 367, 3.52; SO₂NH₂, H, 208.5-10°, 360,
2.82. Relative intensities of fluorescence spectra and lightfastness of I
and II for acetate and polyamide fibers are given: I (R¹ = CO₂H, R² = H),
I (R¹ = CO₂Me, R² = H), and I (R¹ = SO₂NH₂, R² = H) gave good
lightfastness and brightening effect on acetate and polyamide fibers.
Both I and II show inferior dyeability for polyester and polypropylene

14 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1963:403520 CAPLUS
 DN 59:3520
 OREF 59:624c-h.625a
 TI Derivatives of p-hydrazinobenzene-sulfonamide
 AU Lespagnot, Albert; Bar, Denise; Mizon-Campone, Charlotte
 CS Pharm. Chim., Lille
 SO Bulletin de la Societe Chimique de France (1963) 40-50
 CODEN: BSCFAS; ISSN: 0037-8968
 DT Journal
 LA Unavailable
 GI For diagram(s), see printed CA Issue.
 AB p-H2NO2C6GH4NH2 (I) was treated with carbonyl compds. to give products with which were
 I, heated 30-60 min. with salicylaldehyde in 95% alc. containing 10% HOAc.
 gave o-HOCH=CHC6H4NH2C6H4NH2, m. 277° (alc.). Similarly were
 prepared p-H2NO2C6GH4NH2, m. 262°, 202° (alc.), and
 p-H2NO2C6GH4NH2, m. 179-80° (alc.). I, in H2O, heated 2 hrs.
 on a water bath with galactose, NaOAc, and H2SO4, gave the
 p,p'-disulfamoylazozone, m. 210° (H2O) of galactose. A similar
 reaction with glucose was not worked up. I (9.4 g.) refluxed 30 min. with
 2 cc. acrolein in 50 cc. alc. containing 3-5 cc. HOAc, gave 5.9 g. II (R1 = R2
 = H), yellow-green, m. 267-9° (alc. Me2CO). Similarly was prepared
 II (R1 = R2 = Ph), green, m. 175° (alc.). I similarly treated with
 EtO2CCH=CHCO2Et, gave about 96% p-H2NO2C6GH4NH2, (C)O2CCH=CHCO2Et, m.
 168°, which, heated at 200°, gave 73% III (R1 = CO2Et, R2 =
 H) (IV), m. 260-3° (50% alc.). Similarly, but without a solvent,
 was prepared 82% p-H2NO2C6GH4NH2, PhCH=CHCO2H, m. 238° (alc.), which
 was converted to 60% III (R1 = Ph, R2 = H), m. 244-5° (absolute alc.).
 I (3.8 g.) refluxed 1 hr. with 3.4 g. (MeO2CCH2)2CO in 20 cc. HOAc, gave
 6.1 g. III (R1 = MeO2CCH2, R2 = H) (V). Similarly was prepared 90% III (R1 =
 EtO2CCH2, R2 = H), m. 172-4° (50% alc.). V, saponified, gave III (R1
 = EtO2CCH2, R2 = H), m. 225-7° (alc.). I heated with
 HO2CCH=CHCO2Et and HOAc in alc., gave VI, m. 202-4°. I (19 g.),
 boiled 4 hrs. with 12 g. succinic anhydride in 100 cc. HOAc, gave 23.7 g.
 N-(p-sulfamoylphenyl)succinylhydrazide, m. 279-81° (50% alc.).
 Similarly was prepared 75% N-(p-sulfamoylphenyl)phthalylhydrazide, m.
 272-4° (50% alc.). IV, saponified, gave III (R1 = HO2C, R2 = H), m.
 251-2° (95% alc.). IV, with MeNH2, gave III (R1 = MeNHCO, R2 = H),
 m. 201-3° (alc.). Similarly were prepared III (R1 = EtNHCO, R2 = H),
 m. 191-3° (alc.), and III (R1 = Et2NCO, R2 = H) (VII), m.
 171-3° (alc.). IV heated 12 hrs. at 100° in a sealed tube
 with MeI and MeOH, gave VIII (R = EtO2C), m. 178-80° (H2O-alc.).
 Similarly, VII gave VIII (R = Et2NCO), m. 218-20° (H2O-alc.). IV,
 in H2O containing HOAc, treated in an ice bath with 20% NaNO2, gave III (R1 =
 EtO2C, R2 = HO), yellow, m. 230-2°, which, in HOAc-H2O-alc., treated
 with Zn powder, gave III (R1 = EtO2C, R2 = H2N) (IX), m. 261°. IX,
 treated with BzH in 50% alc., gave III (R1 = EtO2C, R2 = PhCH2N), m.
 195-7° (50% alc.).

L4 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
fibers.
IT 10179-57-4. Benzenesulfonamide, p-(3,5-di phenyl-2-pyrazolin-1-yl)-
(preparation of)
RN 10179-57-4 CAPLUS
CN Benzenesulfonamide, 4-(4,5-dihydro-3,5-di phenyl-1H-pyrazol-1-yl)- (9CI)
(CA INDEX NAME)



L4 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



L4 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1961:59466 CAPLUS
 DN 55:59466
 OREF 55:113950-g
 TI Research in the pyrazoline series. III. Synthesis of some
 5-(5-bromo-2-furyl)pyrazolines
 AU Bellotti, Antonio
 CS Univ. Parma, Italy
 SO Annali di Chimica (Rome, Italy) (1960), 50, 1406-12
 CODEN: ANCRAL; ISSN: 0003-4592

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.


AB cf. ibid. 1216-22. In view of their possible anti-tubercular and bacteriostatic activity some substituted 5-(5-bromo-2-furyl)-2-pyrazolines were prepared. Thus, 17.5 g. 5-bromofurfural (I) in 100 ml. EtOH, was poured into a solution containing 0.6 g. NaOH, 200 ml. EtOH, 90 ml. Et Me ketone, and 460 ml. H₂O and the whole stirred 6 hrs. at room temperature to give a yellow oil, which crystallized gave 0.08:CH₃:CH:COH:CH:COH:CH:CH:CH:Br:O, m. 96°; the mother liquors, concentrated in vacuo to about one-third the original volume, gave an oil, which crystallized to give 60% 1-(5-bromofurfurylidene)-1-methylacetone (II), m. 47° (ligroine). II (1 mole) refluxed 1 hr. with 1.1 moles 85% N₂H₄OH in EtOH gave on cooling 5-(5-bromo-2-furyl)-3-methyl-2-pyrazoline (III), m. 87°; yield 75%. By the usual procedures, the following 1-substituted III were prepared from III (1-substituent, m.p., and % yield given): CSNH₂, 180°, 20%; CSNHPh, 144°, 90%; CSNHCO₂H, 151.5°, 65%; CO₂Me, 91.5°, poor. By warming the appropriate unsatd. ketone with PhNNH₂ or its para-substituted derivs., the following phenylhydrazones (IV) were obtained: 0.08:CH₃:CH:COH:CH:COH:CH:CH:CH:Br:O, m.p., and % yield given) H, Me, H, 131°, 75%; H, Me, Me, 121°, 77%; H, Me, Br, 92-3°, 40%; H, Me, SO₂NH₂, 160°, 66%; H, Me, SO₂NHMe, 147-8°, 95%; Me, Me, H, 119°, 60%; Me, Me, Me, 112°, 35%; Me, Me, Br, 123°, 85%; Me, Me, SO₂NH₂, 168°, 60%; Me, Me, SO₂NHMe, 138°, 55%. AcOH solns. of IV, heated to 75-80° on the water bath till their color turned from yellow to red gave the following 0.08:CH₃:CH:COH:CH:COH:CH:CH:CH:Br:O, m.p., and % yield given) H, Me, H, 129°, 70%; H, Me, Me, 108°, 96%; H, Me, Br, 131°, 85%; H, Me, SO₂NH₂, 184.5°, 90%; H, Me, SO₂NHMe, 150.5°, 50%; Me, Me, H, 115°, 80%; Me, Me, Me, 95°, 96%; Me, Me, Br, 137°, 80%; Me, Me, SO₂NH₂, 189°, 60%; Me, Me, SO₂NHMe, 145°, 56%. All the 1-phenyl-substituted pyrazolines gave pos. Knorr reactions.

IT 100709-25-9, Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (preparation of)

RN 100709-25-9 CAPLUS

CN Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (6CI) (CA INDEX NAME)

L4 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1961:57835 CAPLUS
 DN 55:57835
 OREF 55:110751.11076a
 TI Ultraviolet spectra of some 5-(2-furyl)pyrazolines
 AU Bellotti, Antonio; Chierici, Luigi
 CS Univ. Parma, Italy
 SO Bollettino Scientifico della Facolta di Chimica Industriale di Bologna (1960), 18, 152
 CODEN: BSFCAY; ISSN: 0366-3205

DT Journal


LA Unavailable

AB The ultraviolet spectra of 3-methyl-5-(2-furyl)-2-pyrazoline and its 1-AcO, Ph, p-ClPh, p-BrPh, p-PhSO₂NH₂, and CSNH₂ derivs. and the corresponding 5-(5-bromo-2-furyl) compds. were measured in 95% EtOH. The compds. had maximum near 2200 and 2700 Å. (log ε .apprx.4.0). The 5-bromo substituent displaces the wave length of the 1st maximum by .apprx. +50 Å. and the 2nd by .apprx. -20 Å.

IT 100709-25-9, Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-, 100714-94-1, Benzenesulfonamide, p-[5-(2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (spectrum of)


RN 100709-25-9 CAPLUS

CN Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (6CI) (CA INDEX NAME)



RN 100714-94-1 CAPLUS

CN Benzenesulfonamide, 4-[5-(2-furyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]-
 (9CI) (CA INDEX NAME)



=> fil caol

FILE 'CAOLD' ENTERED AT 12:14:10 ON 10 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.


This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13


L5

4 L3


LS ANSWER 1 OF 4 CAOLD COPYRIGHT 2005 ACS on STN
 AN CA65:13850b CAOLD
 TI Fluorescent brighteners for synthetic fibers - (XI) 2-pyrazoline
 Fluorescent brightening agents containing pyridine rings
 AU Horigawa, Takahito; Kawai, M.; Kuroki, N.; Konishi, K.
 IT 959-08-0 1450-62-0 2515-55-1 2515-56-2 2515-57-3 2538-52-5
 2574-33-6 10040-55-8 10040-61-6 10040-65-0 10040-66-1 10040-72-9
 10040-74-1 10040-75-2 10179-51-8 10179-54-1 10179-55-2 10179-56-3
 10179-57-4 10179-69-8 10179-70-1 10179-71-2 10179-72-3
 10180-02-6 10180-07-1 10180-08-2 10180-09-3 13393-39-0 13393-41-4
 13393-42-5
 IT 10179-57-4
 RN 10179-57-4 CAOLD
 CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)]- (9CI)
 (CA INDEX NAME)




LS ANSWER 2 OF 4 CAOLD COPYRIGHT 2005 ACS on STN
 AN CA59:624c CAOLD
 TI derivs. of p-hydrazinobenzenesulfonamide
 AU Lespagnol, Albert; Bar, D.; Mizon-Capron, C.
 IT 10179-57-4 63237-02-5 71401-57-5 90559-42-5 90797-37-8
 90840-94-1 91141-72-9 91560-77-9 91960-19-9 92325-57-0 92327-91-8
 93003-90-8 93188-52-4 93730-72-4 94112-12-6 95877-05-7 98843-37-9
 98904-57-5
 IT 10179-57-4
 RN 10179-57-4 CAOLD
 CN Benzenesulfonamide, 4-[(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)]- (9CI)
 (CA INDEX NAME)




LS ANSWER 3 OF 4 CAOLD COPYRIGHT 2005 ACS on STN
 AN CA55:11395b CAOLD
 TI pyrazoline series - (III) synthesis of some 5-(5-bromo-2-furyl)pyrazolines
 AU Bellotti, Antonio
 IT 24270-95-9 56529-97-6 99070-04-9 100542-45-8 100542-46-9
 100709-25-9 100715-99-9 100716-01-6 101102-78-7 101111-51-7
 101169-91-9 101352-77-6 101352-78-7 101352-79-8 101441-01-4 108373-06-4
 108485-01-4 109098-85-3 109535-63-9 110153-94-1 110175-95-6 114133-60-7
 114765-48-9 130831-52-6 130906-65-9 132700-01-7
 IT 100709-25-9
 RN 100709-25-9 CAOLD
 CN Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (6CI) (CA INDEX NAME)



LS ANSWER 4 OF 4 CAOLD COPYRIGHT 2005 ACS on STN
 AN CA55:110751 CAOLD
 TI ultraviolet spectra of some 5-(2-furyl)pyrazolines
 AU Bellotti, Antonio; Chierici, L.
 IT 13599-33-2 20264-76-0 99070-04-9 100542-46-9 100709-25-9
 100714-94-1 100716-01-6 100716-02-7 101112-18-9 102000-89-5
 108485-01-4 109098-85-3 115229-95-3 132700-01-7
 IT 100709-25-9 100714-94-1
 RN 100709-25-9 CAOLD
 CN Benzenesulfonamide, p-[5-(5-bromo-2-furyl)-3-methyl-2-pyrazolin-1-yl]-
 (6CI) (CA INDEX NAME)



RN 100714-94-1 CAOLD
 CN Benzenesulfonamide, 4-[5-(2-furyl)-4,5-dihydro-3-methyl-1H-pyrazol-1-yl]-
 (9CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 12:09:39 ON 10 FEB 2005)

FILE 'REGISTRY' ENTERED AT 12:09:47 ON 10 FEB 2005

L1 STRUCTURE UPLOADED

L2 9 S L1

L3 127 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:10:35 ON 10 FEB 2005

L4 40 S L3

FILE 'CAOLD' ENTERED AT 12:14:10 ON 10 FEB 2005

L5 4 S L3

FILE 'REGISTRY' ENTERED AT 12:14:54 ON 10 FEB 2005

L6 STRUCTURE UPLOADED

L7 0 S L6

L8 2 S L6 FULL

FILE 'CAPLUS' ENTERED AT 12:15:39 ON 10 FEB 2005

L9 3 S L8

10/630.397


Page 37

=> d 1-3 bib abs hitstr

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN
 AN 2002:793411 CAPLUS
 DN 137:310911
 TI Utilization of pyrazoline derivatives, as inhibitors of the expression of the gene responsible for COX-2 synthesis, in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
 IN Cuberes-Altsent, Maria Rosa; Berrocal-Romero, Juana Maria; Contijoch-Llobet, Maria Montserrat; Frigola-Constans, Jordi
 PA Laboratorios del Esteve, S.A., Spain
 SO PCT Int. Appl., 54 pp.
 CODEN: P1XXD2
 DT Patent
 LA Spanish
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2002080909	A1	20021017	MO 2002-ES137	20020321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, HZ, SD, SL, SZ, TZ, UG, ZH, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TG				
ES 2174757	A1	20021101	ES 2001-818	20010406
ES 2174757	B1	20031101		
EP 1384477	A1	20040128	EP 2002-714233	20020321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 200208805	A	20040713	BR 2002-8805	20020321
JP 2004525166	T2	20040819	JP 2002-578948	20020321
US 2004034082	A1	20040219	US 2002-312193	20021217
NO 2003044470	A	20031205	NO 2003-4470	20031006
PRAI ES 2001-818	A	20010406		
MO 2002-ES137	W	20020321		
OS MARPAT 137:310911				
GI				

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 (Uses)
 (drug candidate; prepn. and use of pyrazoline derivs. as COX-2 gene expression inhibitors for prevention and/or treatment of proliferative cell diseases)
 RN 251443-54-6 CAPLUS
 CN Acetamide, N-[[4-[[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




AB The invention relates to pyrazoline derivs. I [wherein R1 = H, Me, CH2F, CHF2, CF3, CD3, C1-4 alkoxy, carbonyl, CONH2, or cyano; R2 = H or Me; R3, R4, R7, R8 = H, Cl, F, Me, CF3, or OMe; R5, R6 = H, Cl, F, Me, CF3, OMe, OCF3, SO2NH2, or SO2NHAc, provided that 1 of R5 or R6 = SO2Me, SO2NH2, or SO2NHAc, and provided that if R1 = Me, then: R2 = H or Me; R3 and R8 = H, Cl, F, Me, or CF3; R4 = H, F, Me, CF3, or OMe; R5 = F, CF3, CF3O, SO2Me, SO2NH2, or SO2NHAc; R6 = H, Cl, F, Me, CF3, OMe, OCF3, SO2Me, SO2NH2, or SO2NHAc, provided that 1 of the substituents R5 or R6 = SO2Me, SO2NH2, or SO2NHAc; and R7 = H, Cl, F, Me, CF3, or OMe; including physiol. acceptable salts]. I are useful for the prevention or treatment of proliferative cell diseases. In particular, I are useful for treatment of pre-neoplastic or neoplastic processes, tumoral angiogenesis, cachexia, and processes related to tumor necrosis factor (TNF). Generally, I are useful for treating processes where there would be benefit by inhibiting the expression of the gene responsible for the synthesis of cyclooxygenase 2 (COX-2), notably in mammals, and particularly in humans. A list of 84 specific examples is provided, and a similar list of 84 compds. (1 difference) is claimed. Six examples of individual enantiomers are given, the remainder being racemic. For instance, condensation of 2,4-difluorobenzaldehyde with either CH3COCF3 (68%) or the reaction product of LiCH2PO3Et2 with PhN:C(Cl)CF3 (81%) gave (E)-1,1,1-trifluoro-4-(2,4-difluorophenyl)-3-buten-2-one. Cyclocondensation of the latter enone with 4-(H2N)SO2C6H4NH2.HCl gave 61% invention compound (s)-II, which was resolved by chromatog. on CHIRALPAK AS to give (+)- and (-)-II with enantiomeric purities of 99.9% or greater. In tests against human colorectal cancer cell lines HCT59 and T020, (s)-II had IC50 values of 29.87 and 33.87 µM, resp. I also inhibited the induction of COX-2 in JURKAT cells, were active against breast cancer cells in culture (IC50 12-18 µM), inhibited angiogenesis (as determined by induction of expression of VEGF and Tf in cell culture), and inhibited production of TNF-α in the air-pouch model in mice.

IT 251443-54-6P. 1-(4-Acetylaminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole
 RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN
 AN 1999:784081 CAPLUS
 DN 132:12302
 TI Diarylpyrazoles as inhibitors of cyclooxygenase-2
 IN Cuberes-Altsent, Maria Rosa; Berrocal-Romero, Juana Maria; Contijoch-Llobet, Maria Montserrat; Frigola-Constans, Jordi
 PA Laboratorios Del Esteve, S.A., Spain
 SO PCT Int. Appl., 60 pp.
 CODEN: P1XXD2
 DT Patent
 LA Spanish
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 9962884	A1	19991209	MO 1999-ES156	19990527
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GM, ML, MR, NE, SN, TD, TG				
ES 2137136	A1	19991201	ES 1998-1129	19980529
ES 2137136	B1	20000916		
CA 2333475	AA	19991209	CA 1999-2333475	19990527
AU 9939329	A1	19991220	AU 1999-39329	19990527
AU 752001	B2	20020905		
EP 1083171	A1	20010314	EP 1999-922192	19990527
EP 1083171	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9910801	A	20011127	BR 1999-10801	19990527
SI 20580	C	20011231	SI 1999-20042	19990527
JP 2002516908	T2	20020611	JP 2000-552096	19990527
NZ 508990	A	20021220	NZ 1999-508990	19990527
TM 572698	B	20040121	TM 1999-88108709	19990527
AT 265437	E	20040515	AT 1999-922192	19990527
RU 2233272	C2	20040727	RU 2000-133231	19990527
PT 1083171	T	20040930	PT 1999-922192	19990527
NO 2000006029	A	20010126	NO 2000-6029	20001128
LT 4879	B	20020125	LT 2000-108	20001128
US 6353117	B1	20020305	US 2000-701276	20001128
BG 105005	A	20010831	BG 2000-105005	20001129
ZA 2000007638	A	20011113	ZA 2000-7638	20001219
LV 12632	B	20010720	LV 2000-161	20001228
PRAI ES 1998-1129	A	19980529		
MO 1999-ES156	W	19990527		
OS MARPAT 132:12302				
GI				

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Diarylpyrazoles I [R1 = H, Me, CHF, CHF2, CF3, CO2H, alkoxy carbonyl, CN; R2 = H, Me; R3, R4, R7, R8 = H, Cl, F, Me, CF3, OMe; R5 = H, Cl, F, Me, CF3, OMe, OCF3; R6 = SO2Me, SO2NH2, SO2NHAc; R5 = SO2Me, SO2NH2, SO2NHAc; R6 = H, Cl, F, Me, CF3, OMe, OCF3] were prepared for use in treating inflammation and other processes mediated by COX-2. Thus, 2,4-F2C6H3CHO was treated with CF3CO2Me to give (E)-2,4-F2C6H3CH=CHCO2CF3 which was cyclized with 4-H2NSO2C6H4NH2 to give I [R1 = CF3, R2-R4, R7, R8 = H, R5 = SO2Me, R6 = Me] which gave 92% inhibition of COX-2 activity at 40 mg/kg orally in rats.

IT 251443-54-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diarylpyrazoles as inhibitors of cyclooxygenase-2)

RN 251443-54-6 CAPLUS

CN Acetamide, N-[[4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 71203-36-6 CAPLUS

CN Octadecanamide, N-[[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1979:524849 CAPLUS

DN 91:124849

TI Organic luminophors of the pyrazoline series - luminescent constituents of fluorescent pigments

AU Pereyaslova, D. G.; Bondarenko, V. E.; Skripkina, V. T.; Vinetskaya, Yu. M.; Bogdanova, L. I.

CS Nauchno-Proiz. Ob'edin. "Monokristallreaktiv", USSR


S0 Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1979), 45(6), 553-6

CODEN: UKZHAU; ISSN: 0041-6045

DT Journal

LA Russian

GI



AB The addition of 3-(4-difluoromethylsulfonylphenyl)-1,5-diphenyl-4,2-pyrazoline (I) [61102-38-3] to aminosulfonyltoluene-formaldehyde-melamine copolymer (II) [39277-28-6] gave a bright yellow fluorescent pigment with strong light absorption at 564 nm. When I and Rhodamine S [12627-64-4] were added to II the resulting orange-red pigment absorbed strongly at 609 nm. Similarly, a green fluorescent pigment was obtained by adding 1,4-bis[1,5-diphenyl-4,2-3-pyrazolyl]benzene [71203-34-4] and Direct Lightfast Turquoise K [50642-57-4] to II. Other shades of pigments were prepared by adding 1-(4-difluoromethylsulfonylphenyl)-3,5-diphenyl-4,2-pyrazoline [61102-37-2], or pyrazoline sulfonate III, X = H, H2NSO2, or C17H35CONHSO2 (IV) to II. The synthesis of III (X = H) or III (X = H2NSO2) involved reacting sulfonated 4-methoxybenzalacetophenone with PhN:NH [100-63-0] or 4-H2NSO2C6H4N:NH [4392-54-5], resp. Refluxing III (X = H2NSO2) with stearic chloride [112-76-5] gave IV.

IT 71203-36-60, sodium sulfonate salt

RL: USES (Uses)

(luminophors, for fluorescent pigments containing aminosulfonyltoluene-formaldehyde-melamine copolymer)

=> => d que 113

L10	160	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	"REDDY E PREMKUMAR"/AU
L11	73	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	"REDDY M V RAMANA"/AU
L12	205	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L10 OR L11
L13	3	SEA	FILE=CAPLUS	ABB=ON	PLU=ON	L12 AND (PYRAZOLINE OR ?PYRAZOLINE)

=> d 1-3 bib abs

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:900624 CAPLUS
 DN 134:42126
 TI 1-(4-(arylsulfonyl)-3-substituted-5-aryl-2-pyrazolines, method of preparation and use as inhibitors of cyclooxygenase-2
 IN Reddy, E. Premkumar; Reddy, M. V. Ramana
 PA Temple University - of the Commonwealth System of Higher Education, USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PDXD2
 DT Patent
 LA English
 FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2000076983	A1	20001221	MO 2000-US16727	20000616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GI, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NP, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM
 RM: GH, GI, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAT US 1999-139414P P 19990616
 OS CASREACT 134:42126; MARPAT 134:42126
 AB 1-OS02-3-X-5-2-2-pyrazolines (X = trihalomethyl, C1-C6 alkyl, and C6H5OR3R4 (R3, R4 = H, halogen, OH, NO2, C1-C6 alkyl, C1-C6 alkoxy, carboxy, C1-C6 trihaloalkyl, CN); Z = substituted and unsubstituted aryl; Q = substituted and unsubstituted phenyl) or a pharmaceutically acceptable salt thereof, a method of preparation and uses as selective inhibitors of cyclooxygenase-2 activity are claimed. They are useful for treating inflammation and cyclooxygenase-mediated disorders. The compounds of the invention preferably are characterized by a selectivity ratio for cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least .apprx.50, more preferably at least .apprx.100; data are reported for 1-(4-methylphenylsulfonyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline and 1-(phenylsulfonyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline and 1-(4-methylphenylsulfonyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline. The claimed method of preparation comprises reacting trans-ZOH:CHC(O)X with OS02NH2: trans-ZOH:CHC(O)X are prepared from (i) 1,1,1-trihaloacetones or AcX and ZOH or (ii) di-Et methylphosphonate and ZOH.

RE, CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 sulfamylphenylhydrazine or salt thereof.
 RE, CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:900446 CAPLUS
 DN 134:42125
 TI 1-(4-(Sulfonylaryl)-3-substituted-5-aryl-2-pyrazolines, method of preparation and use as inhibitors of cyclooxygenase-2
 IN Reddy, E. Premkumar; Reddy, M. V. Ramana
 PA Temple University - of the Commonwealth System of Higher Education, USA
 SO PCT Int. Appl., 38 pp.
 CODEN: PDXD2
 DT Patent
 LA English
 FAN, CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2000076503	A1	20001221	MO 2000-US16656	20000616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GI, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NP, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM
 RM: GH, GI, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2377153 AA 20001221 CA 2000-2377153 20000616
 EP 1191931 A1 20020403 EP 2000-939946 20000616
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 US 6376519 B1 20020423 US 2000-595760 20000616
 JP 2003501464 T2 20030114 JP 2001-502836 20000616
 NZ 516553 A 20040130 NZ 2000-516553 20000616
 AU 771668 B2 20040401 AU 2000-54951 20000616
 PRAT US 1999-139416P P 19990616
 MO 2000-US16656 W 20000616
 OS MARPAT 134:42125

AB 1-(4-(Sulfonylaryl)-3-X-5-Z-2-pyrazolines (X = trihalomethyl, C1-C6 alkyl, and C6H5OR3R4 (R3, R4 = H, halogen, hydroxyl, nitro, C1-C6 alkyl, C1-C6 alkoxy, carboxy, C1-C6 trihaloalkyl, CN); Z = substituted and unsubstituted aryl) or a pharmaceutically acceptable salt thereof, a method of preparation and uses as inhibitors of cyclooxygenase-2 activity are claimed. They are useful for treating cyclooxygenase-mediated disorders, including, for example, inflammation, neoplastic disorders and angiogenesis-mediated disorders. The compounds of the invention preferably are characterized by a selectivity ratio for cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least .apprx.50, more preferably at least .apprx.100; data are reported for 1-(4-sulfonylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline and 1-(4-sulfonylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline. The claimed method of preparation comprises reacting trans-ZOH:CHC(O)X with 4-

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:532070 CAPLUS
 DN 113:132070
 TI Synthesis and antimicrobial activity of some new bis(2-pyrazolin-3-yl)benzenes
 AU Reddy, D. Bhaskar; Seenalah, B.; Eswaralah, S.; Seshamma, T.; Reddy, M. V. Ramana
 CS Dep. Chem., S. V. Univ., Tirupati, 517 502, India
 SO Journal of the Indian Chemical Society (1989), 66(12), 893-6
 CODEN: JICSAH; ISSN: 0019-4522
 DT Journal
 LA English
 OS CASREACT 113:132070
 GI



AB Several new 3,3'-m-phenylenebis(5-aryl-2-pyrazolines), e.g. I (R = H, Me, Me2CH, MeO, EtO, F, Cl, Br, NO2; R1 = H), have been prepared by reaction of 1,1'-(1,3-phenylene)bis(3-aryl-2-propen-1-ones) m-(4-RC6H4CH:CHCO)2C6H4 with N2H4. The N-substituted derivs. I (R = H, Me, OMe2, EtO, Cl, NO2; R1 = NO, Ac, Bz, PhSO2) have been prepared by nitrosation, acetylation, benzylation, and benzenesulfonylation. Further, 5,5'-p-phenylenebis(3-aryl-2-pyrazolines) II (R2 = H, Me, MeO, EtO, Cl, Br, NH2) were prepared similarly. Structures of the compounds have been confirmed by IR and 1H NMR spectral data. They have been screened against a few microorganisms for antibacterial and antifungal activities.